id,evidence_inference_prompt_id,pmcid,outcome,intervention,comparator,outcome_type,intervention_events,intervention_group_size,comparator_events,comparator_group_size,intervention_mean,intervention_standard_deviation,comparator_mean,comparator_standard_deviation,standardized_mean_difference,smd_sampling_variance,log_odds_ratio,lor_sampling_variance,log_risk_ratio,lrr_sampling_variance,notes,is_data_in_figure_graphics,is_relevant_data_in_table,is_table_in_graphic_format,is_data_complete,openai_gpt_token_num_abstract_results,split,tiktoken_no_attr_token_num
1,11248,57750,Death or myocardial infarction,eptifibatide,placebo,binary,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Group sizes are not given so the events cannot calculate using the percentages.,False,False,False,False,5811,DEV,4777
2,11249,57750,Myocardial infarction,eptifibatide,placebo,binary,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Group sizes are not given so the events cannot calculate using the percentages.,False,False,False,False,5811,DEV,4777
3,11266,1216327,The mean body weight gain,White Grape Juice (WGJ),colored and flavored water (WA),continuous,,30.0,,30.0,50.6,,-0.7,,cannot calculate,cannot calculate,,,,,Missing standard deviations,False,True,False,False,6350,DEV,5198
4,11267,1216327,The duration of the illness,White Grape Juice (WGJ),colored and flavored water (WA),continuous,,30.0,,30.0,47.5,38.9,26.5,27.4,0.6161,0.0698,,,,,,False,True,False,True,6350,DEV,5198
5,11268,1216327,The fecal losses,White Grape Juice (WGJ),colored and flavored water (WA),continuous,,30.0,,30.0,3.59,2.35,2.19,1.63,0.6833,0.0706,,,,,,False,True,False,True,6350,DEV,5198
6,11451,1574360,The amount of saturated fat in the foods purchased,fully automated advice that recommended specific switches from selected products higher in saturated fat to alternate similar products lower in saturated fat,control received general non-specific advice about how to eat a diet lower in saturated fat,continuous,,251.0,,246.0,0.77,1.37,0.04,0.32,0.7273,0.0086,,,,,Have to use CI to calculate the SDs,False,False,True,True,1959,TEST,1620
7,11452,1574360,the average cost of the food,fully automated advice that recommended specific switches from selected products higher in saturated fat to alternate similar products lower in saturated fat,control received general non-specific advice about how to eat a diet lower in saturated fat,continuous,,251.0,,246.0,0.63,0.4,0.62,0.36,0.0261,0.008,,,,,Have to use CI to calculate the SDs,False,False,True,True,1959,TEST,1620
8,9683,2363753,Days with fever,Amifostine,Control,continuous,,20.0,,20.0,,,,,cannot calculate,cannot calculate,,,,,Only abstract is available. Full text in PDF only.,False,False,False,False,887,TEST,780
9,9684,2363753,Hospital stay,Amifostine,Control,continuous,,20.0,,20.0,,,,,cannot calculate,cannot calculate,,,,,Only abstract is available. Full text in PDF only.,False,False,False,False,887,TEST,780
10,9682,2363753,Grade III/IV stomatitis,Amifostine,Control,binary,0.0,20.0,5.0,20.0,,,,,,,-2.6775,2.2951,-2.3979,2.0866,Only abstract is available. Full text in PDF only.,False,False,False,True,887,TEST,780
11,9681,2363753,Glomerular filtration rate fall,Amifostine,Control,continuous,,20.0,,20.0,10.0,,37.0,,cannot calculate,cannot calculate,,,,,Only abstract is available. Full text in PDF only.,False,False,False,False,887,TEST,780
12,12632,2667135,number of days with received courses of antibiotics,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,continuous,,103.0,,97.0,25.4,,13.5,,cannot calculate,cannot calculate,,,,,SD or CI is missing. Mean is given.,False,False,False,False,11722,TEST,8110
13,12633,2667135,proportion of patients completed therapy,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,93.0,103.0,44.0,97.0,,,,,,,2.4161,0.1523,0.6884,0.0135,,False,True,False,True,11722,TEST,8110
14,12634,2667135,early discontinuations,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,10.0,103.0,54.0,97.0,,,,,,,-2.4161,0.1523,-1.7277,0.0988,,False,True,False,True,11722,TEST,8110
15,12635,2667135,rate of clinical success at the test-of-cure visit,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,89.0,103.0,54.0,97.0,,,,,,,1.6218,0.1244,0.4396,0.0097,,False,True,False,True,11722,TEST,8110
16,12636,2667135,deaths,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,binary,4.0,103.0,18.0,97.0,,,,,,,-1.7297,0.3283,-1.5641,0.2855,,False,True,False,True,11722,TEST,8110
17,8237,2681019,Adiponectin in women,Red wine,Control,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Mean and SD in figure. Group sizes not available in results section.,True,False,False,False,726,DEV,647
18,8238,2681019,Adiponectin in men,Ethanol solution,Control,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Mean and SD in figure. Group sizes not available in results section.,True,False,False,False,726,DEV,647
19,8239,2681019,Adiponectin in men,Beer,Control,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Mean and SD in figure. Group sizes not available in results section.,True,False,False,False,726,DEV,647
20,3246,2972614,Adverse effects,Laser therapy (Group I),Placebo laser therapy (Group II),binary,0.0,30.0,0.0,22.0,,,,,,,-0.3042,4.0772,-0.2985,3.9243,,False,False,False,True,7041,TEST,2968
21,3243,2972614,Severity of pain,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,3.76,1.45,4.63,2.1,-0.4889,0.0811,,,,,,False,True,False,True,7041,TEST,2968
22,3245,2972614,Shoulder Pain and Disability Index score,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,48.13,22.1,40.99,20.98,0.325,0.0798,,,,,,False,True,False,True,7041,TEST,2968
23,3247,2972614,Laboratory parameters,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,,,,,cannot calculate,cannot calculate,,,,,Unclear outcome and also no numerical data for this specific outcome,False,False,False,False,7041,TEST,2968
24,3244,2972614,Motion range - Shoulder flexion,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,168.0,22.65,174.31,14.98,-0.314,0.0797,,,,,Outcome originally just Motion range.,False,True,False,False,7041,TEST,2968
25,3244,2972614,Motion range - Shoulder extension,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,42.66,3.4,42.95,3.98,-0.0781,0.0788,,,,,Outcome originally just Motion range.,False,True,False,False,7041,TEST,2968
26,3244,2972614,Motion range - Shoulder abduction,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,166.66,21.38,172.72,16.67,-0.3054,0.0797,,,,,Outcome originally just Motion range.,False,True,False,False,7041,TEST,2968
27,3244,2972614,Motion range - Shoulder adduction,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,42.0,4.27,42.04,5.26,-0.0084,0.0788,,,,,Outcome originally just Motion range.,False,True,False,False,7041,TEST,2968
28,3244,2972614,Motion range - Shoulder internal rotation,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,49.33,9.62,49.77,4.49,-0.055,0.0788,,,,,Outcome originally just Motion range.,False,True,False,False,7041,TEST,2968
29,3244,2972614,Motion range - Shoulder external rotation,Laser therapy (Group I),Placebo laser therapy (Group II),continuous,,30.0,,22.0,44.83,5.64,44.09,1.97,0.1626,0.079,,,,,Outcome originally just Motion range.,False,True,False,False,7041,TEST,2968
30,5576,3003523,Short-Form 36-Items improvement,Certolizumab 200 mg,Control,continuous,,393.0,,199.0,38.1,9.5,31.5,7.4,0.7447,0.008,,,,,Used values for PCS after 52 weeks (final timepoint).,False,True,False,True,12247,TEST,10091
31,5577,3003523,Short-Form 36-Items improvement,Certolizumab 400 mg,Control,continuous,,390.0,,199.0,38.9,8.9,31.5,7.4,0.8773,0.0082,,,,,Used values for PCS after 52 weeks (final timepoint).,False,True,False,True,12247,TEST,10091
32,5580,3003523,Pain,Certolizumab 400 mg,Control,continuous,,390.0,,199.0,53.9,22.2,34.0,20.1,0.9238,0.0083,,,,,Used values for weeks 52 (final timepoint).,False,True,False,True,12247,TEST,10091
33,5575,3003523,Health-related quality of life improvement - Short-Form 36-Items improvement,Certolizumab 200 mg,Control,continuous,,393.0,,199.0,38.1,9.5,31.5,7.4,0.7447,0.008,,,,,This outcome is measured by Short-Form 36-Items (SF-36).,False,False,False,False,12247,TEST,10091
34,5578,3003523,Mental Component Summary improvement,Certolizumab 400 mg,Control,continuous,,390.0,,199.0,45.4,11.5,41.1,10.8,0.3811,0.0077,,,,,Used values for MCS after 52 weeks (final timepoint).,False,True,False,True,12247,TEST,10091
35,5579,3003523,Fatigue Assessment Scale improvement,Certolizumab 200 mg,Control,continuous,,393.0,,199.0,,,,,cannot calculate,cannot calculate,,,,,Values are in figure.,True,False,False,False,12247,TEST,10091
36,6988,3169777,adverse event profile - headache,macitentan dose of 600 mg,placebo,binary,5.0,6.0,3.0,14.0,,,,,,,2.9087,1.6242,1.3581,0.2952,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",False,True,False,True,5143,TEST,4376
37,6985,3169777,unexpected adverse events,macitentan doses of 0.2 mg,placebo,binary,0.0,6.0,0.0,14.0,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,False,False,False,True,5143,TEST,4376
38,6985,3169777,unexpected adverse events,macitentan doses of 1 mg,placebo,binary,0.0,6.0,0.0,14.0,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,False,False,False,True,5143,TEST,4376
39,6985,3169777,unexpected adverse events,macitentan doses of 5 mg,placebo,binary,0.0,6.0,0.0,14.0,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,False,False,False,True,5143,TEST,4376
40,6985,3169777,unexpected adverse events,macitentan doses of 25 mg,placebo,binary,0.0,6.0,0.0,14.0,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,False,False,False,True,5143,TEST,4376
41,6985,3169777,unexpected adverse events,macitentan doses of 100 mg,placebo,binary,0.0,6.0,0.0,14.0,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,False,False,False,True,5143,TEST,4376
42,6985,3169777,unexpected adverse events,macitentan doses of 300 mg,placebo,binary,0.0,6.0,0.0,14.0,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,False,False,False,True,5143,TEST,4376
43,6985,3169777,unexpected adverse events,macitentan doses of 600 mg,placebo,binary,0.0,6.0,0.0,14.0,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,False,False,False,True,5143,TEST,4376
44,6986,3169777,Plasma endothelin-1 concentrations,macitentan dose of 600 mg,placebo,continuous,,6.0,,14.0,,,,,cannot calculate,cannot calculate,,,,,The mean and SD are in bar chart (figure),True,False,False,False,5143,TEST,4376
45,6989,3169777,adverse event profile - headache,macitentan doses of 0.2 mg,placebo,binary,0.0,6.0,3.0,14.0,,,,,,,-1.3754,2.5265,-1.1838,2.0762,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",False,True,False,True,5143,TEST,4376
46,6989,3169777,adverse event profile - headache,macitentan doses of 1 mg,placebo,binary,0.0,6.0,3.0,14.0,,,,,,,-1.3754,2.5265,-1.1838,2.0762,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",False,True,False,True,5143,TEST,4376
47,6989,3169777,adverse event profile - headache,macitentan doses of 5 mg,placebo,binary,0.0,6.0,3.0,14.0,,,,,,,-1.3754,2.5265,-1.1838,2.0762,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",False,True,False,True,5143,TEST,4376
48,6989,3169777,adverse event profile - headache,macitentan doses of 25 mg,placebo,binary,2.0,6.0,3.0,14.0,,,,,,,0.6061,1.1742,0.4418,0.5952,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",False,True,False,True,5143,TEST,4376
49,6989,3169777,adverse event profile - headache,macitentan doses of 100 mg,placebo,binary,1.0,6.0,3.0,14.0,,,,,,,-0.3102,1.6242,-0.2513,1.0952,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",False,True,False,True,5143,TEST,4376
50,6989,3169777,adverse event profile - headache,macitentan doses of 300 mg,placebo,binary,2.0,6.0,3.0,14.0,,,,,,,0.6061,1.1742,0.4418,0.5952,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",False,True,False,True,5143,TEST,4376
51,5308,3195393,Continuous restraint,After restraint reduction program,Before restraint reduction program,continuous,,562.0,,463.0,8.5,0.07,10.8,0.13,-19.6737,0.1927,,,,,Overall continuous restraint rate for study site.,False,True,False,True,15527,TEST,8380
52,5306,3195393,Restraint frecuency,After restraint reduction program,Before restraint reduction program,continuous,,562.0,,463.0,13.6,0.07,11.5,0.13,20.6573,0.2121,,,,,Added intermittent and continuous numbers from study site,False,True,False,True,15527,TEST,8380
53,5307,3195393,Intermittent restraint,After restraint reduction program,Before restraint reduction program,continuous,,562.0,,463.0,5.1,0.07,0.7,0.02,9.6931,0.0498,,,,,Overall intermittent restraint rate for study site.,False,True,False,True,15527,TEST,8380
54,5309,3195393,Restraint knowledge,After restraint reduction program,Before restraint reduction program,continuous,,562.0,,463.0,6.23,,5.51,,cannot calculate,cannot calculate,,,,,No SD information provided,False,False,False,False,15527,TEST,8380
55,10673,3276927,relieving factors in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19.0,,19.0,,,,,cannot calculate,cannot calculate,,,,,Data found in table in graphic format.,False,True,True,False,2011,DEV,1731
56,10676,3276927,effective in the treatment of reversible inguinal hernia,post-Yoga,pre-Yoga,binary,,19.0,,19.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,"No real numerical data attached to this specific outcome. Other prompts account for ""treatment""",False,False,True,False,2011,DEV,1731
57,10672,3276927,frequency of occurrence in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19.0,,19.0,,,,,cannot calculate,cannot calculate,,,,,Only median and range is given.,False,True,True,False,2011,DEV,1731
58,10671,3276927,"symptoms of hernia such as heaviness, fullness and pain",post-Yoga,pre-Yoga,continuous,,19.0,,19.0,,,,,cannot calculate,cannot calculate,,,,,No specific numerical data associated with these symptoms.,False,False,True,False,2011,DEV,1731
59,10674,3276927,pain in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19.0,,19.0,,,,,cannot calculate,cannot calculate,,,,,Only median and range is given.,False,True,True,False,2011,DEV,1731
60,10675,3276927,aggravating factors in reversible inguinal hernia,post-Yoga,pre-Yoga,continuous,,19.0,,19.0,,,,,cannot calculate,cannot calculate,,,,,Only median and range is given.,False,True,True,False,2011,DEV,1731
61,1642,3309311,differences in the disc herniation,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,,23.0,,19.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Data is in graphic table.,False,True,True,True,1437,TEST,1263
62,1642,3309311,differences in the HDD,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,,23.0,,19.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Data is in graphic table.,False,True,True,True,1437,TEST,1263
63,1642,3309311,differences in the annulus tear,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,,23.0,,19.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Data is in graphic table.,False,True,True,True,1437,TEST,1263
64,1642,3309311,differences in the HIZ,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,,23.0,,19.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Data is in graphic table.,False,True,True,True,1437,TEST,1263
65,1644,3309311,The proportion of HIZ incidence,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)",adults with LBP with radicular pain (group C),binary,14.0,23.0,3.0,18.0,,,,,,,2.0513,0.5825,1.2953,0.3057,Used percentage to calculate events as binary outcome.,False,False,True,True,1437,TEST,1263
66,1643,3309311,The proportion of HIZ incidence,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",binary,14.0,23.0,4.0,19.0,,,,,,,1.7636,0.4992,1.0617,0.2253,Used percentage to calculate events as binary outcome.,False,False,True,True,1437,TEST,1263
67,3041,3321528,wrist flexion,electrical muscle stimulation (EMS),control,continuous,,24.0,,28.0,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,False,True,False,False,6725,TEST,3999
68,3041,3321528,hip flexion,electrical muscle stimulation (EMS),control,continuous,,24.0,,28.0,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,False,True,False,False,6725,TEST,3999
69,3041,3321528,knee extension,electrical muscle stimulation (EMS),control,continuous,,24.0,,28.0,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,False,True,False,False,6725,TEST,3999
70,3041,3321528,ankle dorsiflexion,electrical muscle stimulation (EMS),control,continuous,,24.0,,28.0,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,False,True,False,False,6725,TEST,3999
71,3043,3321528,handgrip strength,Intensive Care Unit acquired weakness (ICU-AW),without an ICU-AW diagnosis,continuous,,,,,6.6,4.4,23.4,8.9,cannot calculate,cannot calculate,,,,,Does not have group size information in article.,False,False,False,False,6725,TEST,3999
72,3042,3321528,the total MRC score of the legs,electrical muscle stimulation (EMS),control,continuous,,24.0,,28.0,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,False,False,False,False,6725,TEST,3999
73,3741,3546023,Urine cotinine levels,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,30.0,,19.0,1.179,0.738,0.047,0.017,2.0036,0.1541,,,,,Values are for week 24 (only timepoint after intervention).,False,True,False,True,29733,TEST,18035
74,3742,3546023,serum α1-antitrypsin,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,30.0,,19.0,1.75,0.39,1.45,0.24,0.867,0.0936,,,,,Values are for week 24 (only timepoint after intervention).,False,True,False,True,29733,TEST,18035
75,3743,3546023,The percentage of B cells,200 mg/day palmvitee nonsmokers,baseline,continuous,,29.0,,29.0,11.97,4.0,13.72,4.53,-0.404,0.0704,,,,,Values are between baseline and week 24 (final timepoint).,False,True,False,True,29733,TEST,18035
76,3744,3546023,The percentage of B cells,200 mg/day palmvitee smokers,baseline,continuous,,30.0,,30.0,14.06,3.81,14.4,4.03,-0.0856,0.0667,,,,,Values are between baseline and week 24 (final timepoint).,False,True,False,True,29733,TEST,18035
77,3746,3546023,The percentage of NK cells,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,30.0,,29.0,19.03,7.82,24.72,8.78,-0.6721,0.0716,,,,,Values are between baseline and week 24 (final timepoint).,False,True,False,True,29733,TEST,18035
78,3740,3546023,tocopherol levels,200 mg/day palmvitee smokers,baseline,continuous,,30.0,,30.0,14.11,3.89,11.39,3.06,0.7671,0.0716,,,,,Values are between baseline and week 24 (final timepoint).,False,True,False,True,29733,TEST,18035
79,3740,3546023,tocotrienol levels,200 mg/day palmvitee smokers,baseline,continuous,,30.0,,30.0,587.68,87.5,59.49,4.21,8.4162,0.6569,,,,,Values are between baseline and week 24 (final timepoint).,False,True,False,True,29733,TEST,18035
80,3740,3546023,tocopherol levels,200 mg/day palmvitee nonsmokers,baseline,continuous,,29.0,,29.0,14.56,3.06,11.75,2.27,1.029,0.0781,,,,,Values are between baseline and week 24 (final timepoint).,False,True,False,True,29733,TEST,18035
81,3740,3546023,tocotrienol levels,200 mg/day palmvitee nonsmokers,baseline,continuous,,29.0,,29.0,675.16,150.0,63.6,5.67,5.6842,0.3475,,,,,Values are between baseline and week 24 (final timepoint).,False,True,False,True,29733,TEST,18035
82,3745,3546023,CD4+/CD8+ ratio,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,continuous,,30.0,,29.0,1.19,0.43,1.03,0.53,0.3277,0.0687,,,,,Values are for week 24 (final timepoint).,False,True,False,True,29733,TEST,18035
83,11789,3580751,mean ± SD length of hospital stay between periods 1 and 2 in patients who did not suffer from VAP,Interrupted surveillance unit A,"Continuous surveillance, unit B",continuous,,940.0,,1831.0,9.9,14.8,9.1,9.9,0.0678,0.0016,,,,,Values are from post-intervention.,False,False,False,True,5335,DEV,4760
84,13566,3687098,adverse event of constipation,sitagliptin 100 mg/day,comparator agent,binary,178.0,7726.0,124.0,6885.0,,,,,,,0.2514,0.014,0.2463,0.0134,Used incidence rate per 100 to get the binary events.,False,True,False,True,15196,TEST,10904
85,13567,3687098,The incidence rates of malignancy,sitagliptin 100 mg/day,comparator agent,binary,6953.0,7726.0,6403.0,6885.0,,,,,,,-0.3899,0.0037,-0.0328,0,Used incidence rate per 100 to get the binary events.,False,False,False,True,15196,TEST,10904
86,13568,3687098,The incidence rates of pancreatitis,sitagliptin 100 mg/day,comparator agent,binary,773.0,7726.0,689.0,6885.0,,,,,,,-0.0002,0.0031,-0.0002,0.0025,Used incidence rate per 100 to get the binary events.,False,True,False,True,15196,TEST,10904
87,13569,3687098,The incidence of the composite endpoint of rash,sitagliptin 100 mg/day,comparator agent,binary,131.0,7726.0,76.0,6885.0,,,,,,,0.4352,0.0211,0.4292,0.0205,Used incidence rate per 100 to get the binary events.,False,True,False,True,15196,TEST,10904
88,13244,3751573,improvement in nursing,phase I externship program,phase II corporate-academic cooperation program,continuous,,19.0,,23.0,117.63,19.01,158.52,23.19,-1.8738,0.1379,,,,,Used post-intervention values.,False,True,False,True,8149,DEV,5521
89,5538,3912320,Correct response rate for 500 Hz frequency,Occupational noise,Control,continuous,,19.0,,10.0,,,,,cannot calculate,cannot calculate,,,,,Mean were in a figure and SD was not given anywhere.,True,False,False,False,1648,TEST,1217
90,5540,3912320,"Correct response rate for 4,000 Hz frequency",Occupational noise,Control,continuous,,19.0,,10.0,,,,,cannot calculate,cannot calculate,,,,,Mean were in a figure and SD was not given anywhere.,True,False,False,False,1648,TEST,1217
91,5539,3912320,"Correct response rate for 2,000 Hz frequency",Occupational noise,Control,continuous,,19.0,,10.0,,,,,cannot calculate,cannot calculate,,,,,Mean were in a figure and SD was not given anywhere.,True,False,False,False,1648,TEST,1217
92,10164,4173437,Postoperatively hematocrit,Tranexamic acid,Control,continuous,,30.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,Had to infer that the group sizes were equal. Data is in table in graphic format.,False,True,True,False,854,TEST,745
93,10166,4173437,Complications,Tranexamic acid,Control,binary,0.0,30.0,0.0,30.0,,,,,,,0,4.0656,0,3.9355,Had to infer that the group sizes were equal.,False,False,True,True,854,TEST,745
94,10167,4173437,Adverse effects,Tranexamic acid,Control,binary,0.0,30.0,0.0,30.0,,,,,,,0,4.0656,0,3.9355,Had to infer that the group sizes were equal.,False,False,True,True,854,TEST,745
95,10163,4173437,Total blood loss,Tranexamic acid,Control,continuous,,30.0,,30.0,576.0,53.0,823.0,74.0,-3.7878,0.1862,,,,,Had to infer that the group sizes were equal.,False,False,True,True,854,TEST,745
96,10165,4173437,Coagulation profile,Tranexamic acid,Control,continuous,,30.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,Had to infer that the group sizes were equal. Data is in table in graphic format.,False,True,True,False,854,TEST,745
97,10168,4173437,Crystalloid solution needed,Tranexamic acid,Control,continuous,,30.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,Had to infer that the group sizes were equal. No numerical values associated with this outcome.,False,False,True,False,854,TEST,745
98,931,4183415,completion of each dose at the correct time,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,continuous,,40.0,,37.0,33.1,21.6,32.6,18.4,0.0246,0.052,,,,,Data found in Table 6.,False,True,False,True,10420,TEST,7106
99,929,4183415,patient adherence,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,continuous,,40.0,,37.0,68.3,23.4,69.8,20.9,-0.0668,0.0521,,,,,"Data found in Table 6. Used same values as ""completed treatment""",False,True,False,True,10420,TEST,7106
100,930,4183415,Completed treatment,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,continuous,,40.0,,37.0,68.3,23.4,69.8,20.9,-0.0668,0.0521,,,,,Data found in Table 6.,False,True,False,True,10420,TEST,7106
101,1886,4188762,heart rate,remifentanil,normal saline,continuous,,30.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,True,False,2068,TEST,1758
102,1886,4188762,heart rate,remifentanil,lidocaine,continuous,,30.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,True,False,2068,TEST,1758
103,1886,4188762,heart rate,remifentanil,ketamine,continuous,,30.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,True,False,2068,TEST,1758
104,1885,4188762,mean blood pressure,remifentanil,normal saline,continuous,,30.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,True,False,2068,TEST,1758
105,1885,4188762,mean blood pressure,remifentanil,lidocaine,continuous,,30.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,True,False,2068,TEST,1758
106,1885,4188762,mean blood pressure,remifentanil,"normal saline, lidocaine, or ketamine",continuous,,30.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,True,False,2068,TEST,1758
107,1884,4188762,withdrawal response of rocuronium,lidocaine,normal saline,binary,6.0,30.0,26.0,30.0,,,,,,,-3.2581,0.4968,-1.4663,0.1385,Used percentage to calculate events as binary outcome.,False,False,True,True,2068,TEST,1758
108,1884,4188762,withdrawal response of rocuronium,ketamine,normal saline,binary,9.0,30.0,26.0,30.0,,,,,,,-2.7191,0.4472,-1.0609,0.0829,Used percentage to calculate events as binary outcome.,False,False,True,True,2068,TEST,1758
109,1884,4188762,withdrawal response of rocuronium,remifentanil,normal saline,binary,0.0,30.0,26.0,30.0,,,,,,,-5.8839,2.2927,-3.9703,1.9732,Used percentage to calculate events as binary outcome.,False,False,True,True,2068,TEST,1758
110,9521,4319071,High-energy snack intake,Individual cognition and self-regulation processes intervention,Control,continuous,,459.0,,434.0,2.5,2.79,2.84,2.71,-0.1235,0.0045,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,False,True,False,True,26475,TEST,16822
111,9522,4319071,High-energy snack intake,Intervention + targeting environmental-level factors,Control,continuous,,456.0,,434.0,2.5,2.76,2.84,2.71,-0.1242,0.0045,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,False,True,False,True,26475,TEST,16822
112,9525,4319071,Vegetable intake,Intervention + targeting environmental-level factors,Control,continuous,,456.0,,434.0,167.61,83.71,158.67,78.33,0.1101,0.0045,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,False,True,False,True,26475,TEST,16822
113,9526,4319071,Vegetable intake,Intervention + targeting environmental-level factors,Individual cognition and self-regulation processes intervention,continuous,,456.0,,459.0,167.61,83.71,173.28,81.63,-0.0685,0.0044,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,False,True,False,True,26475,TEST,16822
114,9523,4319071,Fruit intake,Intervention + targeting environmental-level factors,Control,continuous,,456.0,,434.0,2.17,1.71,2.0,1.67,0.1005,0.0045,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,False,True,False,True,26475,TEST,16822
115,9524,4319071,Fruit intake,Intervention + targeting environmental-level factors,Individual cognition and self-regulation processes intervention,continuous,,456.0,,459.0,2.17,1.71,2.14,1.71,0.0175,0.0044,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,False,True,False,True,26475,TEST,16822
116,2982,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Deep-cooling,Mild-cooling,continuous,,9.0,,10.0,,,70.0,,cannot calculate,cannot calculate,,,,,,False,True,True,False,3049,TEST,2670
117,2983,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Deep-cooling,No cooling,continuous,,9.0,,13.0,,,15.4,,cannot calculate,cannot calculate,,,,,,False,True,True,False,3049,TEST,2670
118,2984,4323894,Rate of complications,Mild-cooling or deep-cooling,No cooling,binary,,10.0,,13.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,,False,True,True,False,3049,TEST,2670
119,2981,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Mild-cooling,No cooling,continuous,,10.0,,13.0,70.0,,15.4,,cannot calculate,cannot calculate,,,,,,False,True,True,False,3049,TEST,2670
120,3102,4450164,ureteropelvic junction obstruction,internal drainage group,stentless cases,binary,8.0,20.0,13.0,44.0,,,,,,,0.4636,0.3175,0.3029,0.1292,,False,True,False,True,3862,DEV,2242
121,7938,4486927,"The SVR rates if the patients had IL-28B rs8099917 TT genotype, and GT/GG genotype",peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,17.0,23.0,2.0,24.0,,,,,,,3.4393,0.7709,2.1826,0.4737,"Even though the outcome says rate, the way that the results are reported in the table makes it easier to calculate as binary outcome.",False,True,False,True,14472,TEST,7883
122,7936,4486927,The early virologic response (EVR),peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,86.0,94.0,82.0,93.0,,,,,,,0.3661,0.2397,0.0369,0.0024,,False,True,False,True,14472,TEST,7883
123,7936,4486927,the end-of-treatment virologic response,peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,83.0,94.0,75.0,93.0,,,,,,,0.5938,0.1718,0.0907,0.004,,False,True,False,True,14472,TEST,7883
124,7937,4486927,The SVR rates when the patients had BMI >30 kg/m2,peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,binary,10.0,19.0,6.0,12.0,,,,,,,0.1054,0.5444,0.0513,0.1307,"Even though the outcome says rate, the way that the results are reported in the table makes it easier to calculate as binary outcome.",False,True,False,True,14472,TEST,7883
125,4926,4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,and H2 (haloperidol 2 mg),H0 (saline),continuous,,50.0,,50.0,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,True,False,False,False,3932,TEST,3205
126,4926,4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,and H2 (haloperidol 2 mg),H1(haloperidol 1 mg),continuous,,50.0,,49.0,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,True,False,False,False,3932,TEST,3205
127,4924,4493951,the incidence of postoperative nausea and vomiting (PONV),H1(haloperidol 1 mg),H0 (saline),binary,11.0,49.0,21.0,50.0,,,,,,,-0.9169,0.1993,-0.6264,0.0981,Used numbers from Late time (2–24 h),False,True,False,True,3932,TEST,3205
128,4924,4493951,the incidence of postoperative nausea and vomiting (PONV),H2 (haloperidol 2 mg),H0 (saline),binary,10.0,50.0,21.0,50.0,,,,,,,-1.0635,0.2071,-0.7419,0.1076,Used numbers from Late time (2–24 h),False,True,False,True,3932,TEST,3205
129,4927,4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,H0 (saline),"H1(haloperidol 1 mg),",continuous,,50.0,,49.0,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,True,False,False,False,3932,TEST,3205
130,4925,4493951,the incidence of postoperative nausea and vomiting (PONV),H1(haloperidol 1 mg),H2 (haloperidol 2 mg),binary,11.0,49.0,10.0,50.0,,,,,,,0.1466,0.2422,0.1155,0.1505,Used numbers from Late time (2–24 h),False,True,False,True,3932,TEST,3205
131,2451,4574984,numbers overall complications,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",binary,238.0,326.0,241.0,326.0,,,,,,,-0.0472,0.0315,-0.0125,0.0022,,False,True,False,True,12997,TEST,7944
132,2452,4574984,level of postoperative pain,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",binary,234.0,326.0,261.0,326.0,,,,,,,-0.4566,0.0344,-0.1092,0.002,,False,True,False,True,12997,TEST,7944
133,2453,4574984,overall mortality,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",binary,45.0,326.0,58.0,326.0,,,,,,,-0.3011,0.0468,-0.2538,0.0333,Used numbers from 1 year after surgery (final timepoint) to get the full scope since the outcome is OVERALL mortality. This info is found in Figure 6 caption.,False,False,False,True,12997,TEST,7944
134,2449,4574984,Health-Related Quality of Life at 12 month - females,"intervention group, i.e. patient empowerment through information booklet and diary keeping - females","control group, which received standard care - females",continuous,,110.0,,95.0,61.07,30.21,63.27,24.79,-0.0788,0.0196,,,,,Group sizes was inferred using Table of characterisitics. Back calculated SD using CI.,False,False,False,False,12997,TEST,7944
135,2450,4574984,Health-Related Quality of Life at 12 month - males,"intervention group, i.e. patient empowerment through information booklet and diary keeping - males","control group, which received standard care - males",continuous,,216.0,,231.0,72.49,23.66,71.71,27.1,0.0305,0.009,,,,,Group sizes was inferred using Table of characterisitics. Back calculated SD using CI.,False,False,False,False,12997,TEST,7944
136,2448,4574984,postoperative in-hospital stay,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",continuous,,326.0,,326.0,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,False,False,False,False,12997,TEST,7944
137,1267,4709985,would have liked more information on acupuncture,tertiary education,other educations,binary,,121.0,,89.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Specific numbers were not given.,False,False,False,False,3939,TEST,3288
138,3101,4830045,Birth status,Patients in the 3h group,Patients in the 20h group,binary,32.0,74.0,22.0,60.0,,,,,,,1 0.2746,0.1268,0.165,0.0465,Used numbers for live birth rate.,False,True,False,True,2530,TEST,2096
139,3100,4830045,Embryo quality,Patients in the 3h group,Patients in the 20h group,binary,,74.0,,60.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Unclear outcome measures.,False,False,False,False,2530,TEST,2096
140,1275,4880652,SpO2 at 5 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76.0,,70.0,,,,,cannot calculate,cannot calculate,,,,,Mean in figure 5's graphics.,True,False,True,False,1406,TEST,1149
141,1272,4880652,the modified Aldrete scores at 60 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76.0,,70.0,,,,,cannot calculate,cannot calculate,,,,,Mean and SD are in table that is in graphic form.,False,True,True,False,1406,TEST,1149
142,1272,4880652,systolic pressures at 0 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76.0,,70.0,,,,,cannot calculate,cannot calculate,,,,,Mean in figure 3's graphics.,True,False,True,False,1406,TEST,1149
143,1272,4880652,"oxygen saturation at 10, 15, 20 minutes",fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76.0,,70.0,,,,,cannot calculate,cannot calculate,,,,,Means in figure 5's graphics.,True,False,True,False,1406,TEST,1149
144,1272,4880652,"diastolic blood pressure at 10, 15, 20 minutes",fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76.0,,70.0,,,,,cannot calculate,cannot calculate,,,,,Means in figure 4's graphics.,True,False,True,False,1406,TEST,1149
145,1272,4880652,heart rates,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76.0,,70.0,,,,,cannot calculate,cannot calculate,,,,,Means in figure 2's graphics.,True,False,True,False,1406,TEST,1149
146,1272,4880652,visual analogue scores,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76.0,,70.0,,,,,cannot calculate,cannot calculate,,,,,Mean and SD are in table that is in graphic form.,False,True,True,False,1406,TEST,1149
147,1273,4880652,"systolic blood pressures at 5, 10, 15, and 20 minutes",fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76.0,,70.0,,,,,cannot calculate,cannot calculate,,,,,Means in figure 3's graphics.,True,False,True,False,1406,TEST,1149
148,1274,4880652,Diastolic blood pressures at 5 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,continuous,,76.0,,70.0,,,,,cannot calculate,cannot calculate,,,,,Mean in figure 4's graphics.,True,False,True,False,1406,TEST,1149
149,11146,4996097,"""a"" vowel improvement",Septoplasty,Control,continuous,,33.0,,30.0,138.0,,154.0,,cannot calculate,cannot calculate,,,,,Used F0 (Hz) values. SD is not given.,False,True,False,False,9291,TEST,4535
150,11145,4996097,Total nasal resistance,Septoplasty,Control,continuous,,33.0,,30.0,0.25,,0.27,,cannot calculate,cannot calculate,,,,,Used preoperative values. SD is not given.,False,True,False,False,9291,TEST,4535
151,11147,4996097,"""n"" consonant improvement",Septoplasty,Control,continuous,,33.0,,30.0,11897.0,,13229.0,,cannot calculate,cannot calculate,,,,,Used F0 (Hz) values. SD is not given.,False,True,False,False,9291,TEST,4535
152,13479,5055753,The percentages of patients in the calm,0.2 mg oral clonidine,2 mg oral midazolam,binary,14.0,40.0,7.0,40.0,,,,,,,0.9316,0.2831,0.6931,0.1643,"Even though the outcome says percentage, the way that the results are reported in the table makes it easier to calculate as binary outcome.",False,False,False,True,3292,TEST,2470
153,13479,5055753,The percentages of patients in the sedated scale,0.2 mg oral clonidine,2 mg oral midazolam,binary,17.0,40.0,7.0,40.0,,,,,,,1.2483,0.2755,0.8873,0.1517,"Even though the outcome says percentage, the way that the results are reported in the table makes it easier to calculate as binary outcome.",False,False,False,True,3292,TEST,2470
154,13480,5055753,the percentages of patients in the agitated sedation scale,0.2 mg oral clonidine,2 mg oral midazolam,binary,,40.0,,40.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,,True,False,False,False,3292,TEST,2470
155,13480,5055753,the percentages of patients in the heavily sedated,0.2 mg oral clonidine,2 mg oral midazolam,binary,,40.0,,40.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,,True,False,False,False,3292,TEST,2470
156,13481,5055753,The mean ¬± SD of intraoperatively administered fentany,0.2 mg oral clonidine,2 mg oral midazolam,continuous,,40.0,,40.0,105.0,30.8,165.0,34.5,-1.817,0.0706,,,,,,False,False,False,True,3292,TEST,2470
157,13482,5055753,Mean ± SD of heart rate,0.2 mg oral clonidine,2 mg oral midazolam,continuous,,40.0,,40.0,,,,,cannot calculate,cannot calculate,,,,,Info in figure graphics.,True,False,False,False,3292,TEST,2470
158,7710,5056957,Weight reduction at 12 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,592.0,,459.0,55.91,15.64,56.48,14.76,-0.0373,0.0039,,,,,Back calculated the SD values from CI,False,True,False,True,11185,TEST,6045
159,7710,5056957,BMI reduction at 12 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,592.0,,459.0,21.07,6.39,21.27,5.9,-0.0323,0.0039,,,,,Back calculated the SD values from CI,False,True,False,True,11185,TEST,6045
160,7711,5056957,BMI z-score at 12months,Multi-component physical activity,Usual PE and sport programmes,continuous,,592.0,,459.0,0.61,1.8,0.66,1.69,-0.0285,0.0039,,,,,Back calculated the SD values from CI,False,True,False,True,11185,TEST,6045
161,7712,5056957,Weight reduction at 24 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,560.0,,425.0,61.08,15.15,61.94,14.25,-0.0582,0.0041,,,,,Back calculated the SD values from CI,False,True,False,True,11185,TEST,6045
162,7712,5056957,BMI reduction at 24 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,560.0,,425.0,21.86,6.22,22.06,5.68,-0.0333,0.0041,,,,,Back calculated the SD values from CI,False,True,False,True,11185,TEST,6045
163,7713,5056957,BMI z-score at 24 months,Multi-component physical activity,Usual PE and sport programmes,continuous,,560.0,,425.0,0.69,1.81,0.71,1.63,-0.0115,0.0041,,,,,Back calculated the SD values from CI,False,True,False,True,11185,TEST,6045
164,617,5062234,The visual analog scale scores at rest and on coughing,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,continuous,,21.0,,21.0,,,,,cannot calculate,cannot calculate,,,,,Data found in table in graphic format.,False,True,True,False,1345,TEST,1148
165,615,5062234,The 24 h morphine requirement,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,continuous,,21.0,,21.0,34.57,14.64,32.76,14.34,0.1225,0.0954,,,,,,False,False,True,True,1345,TEST,1148
166,616,5062234,intraoperative supplemental fentanyl,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,binary,8.0,21.0,16.0,21.0,,,,,,,-1.6487,0.4644,-0.6931,0.0923,,False,False,True,True,1345,TEST,1148
167,2797,5079604,Disposition index (DI),subjects who remained in remission,patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si),continuous,,28.0,,20.0,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,True,False,False,False,12690,TEST,6902
168,2797,5079604,incremental area under the curve for insulin (AUCi),subjects who remained in remission,patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si),continuous,,28.0,,20.0,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,True,False,False,False,12690,TEST,6902
169,2792,5079604,hyperglycemia relapse-free survival,"metformin 1,000 mg daily",sitagliptin 100 mg daily,continuous,,17.0,,16.0,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,True,False,False,False,12690,TEST,6902
170,2795,5079604,Cox proportional hazards of failure-free survival,"metformin 1,000 mg daily",sitagliptin 100 mg daily,continuous,,17.0,,16.0,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,True,False,False,False,12690,TEST,6902
171,2793,5079604,The restricted mean time to hyperglycemia relapse,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,continuous,,33.0,,15.0,480.0,,305.0,,cannot calculate,cannot calculate,,,,,SD is not given.,False,False,False,False,12690,TEST,6902
172,2790,5079604,Hyperglycemia relapse-free survival,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,continuous,,33.0,,15.0,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,True,False,False,False,12690,TEST,6902
173,2791,5079604,The 2-year failure rate,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,binary,13.0,33.0,12.0,15.0,,,,,,,-1.8171,0.5436,-0.7084,0.0633,Used percentage to calculate events as binary outcome.,True,True,False,True,12690,TEST,6902
174,2796,5079604,The probability of relapse,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,binary,9.0,33.0,11.0,15.0,,,,,,,-1.9924,0.4937,-0.9891,0.1051,Used percentage to calculate events as binary outcome.,False,False,False,True,12690,TEST,6902
175,10752,5086025,Intuitive eating total score,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26.0,,26.0,3.45,0.55,2.54,0.58,1.5858,0.1011,,,,,Actually comparing preintervention and postintervention,False,True,False,True,29049,TEST,17627
176,10753,5086025,Psychological flexibility,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26.0,,26.0,18.23,8.14,22.46,8.67,-0.4954,0.0793,,,,,Actually psychological inflexibility in the article,False,True,False,True,29049,TEST,17627
177,10754,5086025,General mental health,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26.0,,26.0,50.24,7.41,45.63,6.31,0.6598,0.0811,,,,,,False,True,False,True,29049,TEST,17627
178,10755,5086025,Binge eating,Intuitive Eating and Acceptance and Commitment Therapy,Control,binary,7.0,26.0,14.0,26.0,,,,,,,-1.1527,0.3503,-0.6931,0.1374,,False,False,False,True,29049,TEST,17627
179,10756,5086025,BMI,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26.0,,26.0,32.81,5.31,32.93,4.85,-0.0232,0.0769,,,,,,False,True,False,True,29049,TEST,17627
180,10757,5086025,General physical health,Intuitive Eating and Acceptance and Commitment Therapy,Control,continuous,,26.0,,26.0,50.87,11.02,50.46,7.83,0.0422,0.0769,,,,,,False,True,False,True,29049,TEST,17627
181,4339,5122613,Left SCTT,Digestion-resistant maltodextrin,Placebo,continuous,,29.0,,28.0,10.2,8.6,12.1,9.5,-0.207,0.0706,,,,,Had to do some simple math to get accurate group size.,False,True,False,True,6184,TEST,3742
182,4340,5122613,Adverse events,Digestion-resistant maltodextrin,Placebo,binary,0.0,33.0,0.0,33.0,,,,,,,0,4.0597,0,3.9412,Based on abstract.,False,False,False,True,6184,TEST,3742
183,4341,5122613,Baseline characteristics and diet,Digestion-resistant maltodextrin,Placebo,continuous,,33.0,,33.0,10.0,4.6,11.5,4.6,-0.3222,0.0614,,,,,Mean daily fiber intake,False,False,False,True,6184,TEST,3742
184,4337,5122613,Improvement in faeces consistency,Digestion-resistant maltodextrin,Placebo,continuous,,33.0,,33.0,3.4,1.0,3.2,0.5,0.25,0.0611,,,,,,False,True,False,True,6184,TEST,3742
185,4338,5122613,Colonic transit time,Digestion-resistant maltodextrin,Placebo,continuous,,29.0,,28.0,39.7,22.3,48.0,25.0,-0.3459,0.0712,,,,,,False,True,False,True,6184,TEST,3742
186,13818,5244530,depression severity reduction,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125.0,,133.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,False,False,6216,DEV,5516
187,13818,5244530,remission rate,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125.0,,133.0,,,,,cannot calculate,cannot calculate,,,,,,False,False,False,False,6216,DEV,5516
188,13818,5244530,change in quality of life,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125.0,,133.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,False,False,6216,DEV,5516
189,13818,5244530,psychological well-being,person-centred general practitioners (GP) consultations,treatment as usual (TAU),continuous,,125.0,,133.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,False,False,6216,DEV,5516
190,13818,5244530,sedative prescriptions,person-centred general practitioners (GP) consultations,treatment as usual (TAU),binary,52.0,125.0,51.0,133.0,,,,,,,0.1357,0.0647,0.0815,0.0233,Data from 12 months follow up (final timepoint),False,True,False,True,6216,DEV,5516
191,13818,5244530,sick leave,person-centred general practitioners (GP) consultations,treatment as usual (TAU),binary,49.0,125.0,64.0,133.0,,,,,,,-0.3637,0.0637,-0.205,0.0205,,False,True,False,True,6216,DEV,5516
192,13819,5244530,continued antidepressants until the 6-month,person-centred general practitioners (GP) consultations,treatment as usual (TAU),binary,86.0,125.0,78.0,133.0,,,,,,,0.4414,0.0683,0.1597,0.0089,,False,True,False,True,6216,DEV,5516
193,2094,5360580,Plasma PlsPE,1 mg/day of Pls purified from scallop,placebo,continuous,,138.0,,131.0,-0.59,1.11,-0.63,1.08,0.0364,0.0149,,,,,Data is from after 28 weeks (final timepoint). Back calculated the SD values using CI values.,False,True,False,True,11096,TEST,9099
194,2095,5360580,occurrence of adverse events,1 mg/day of Pls purified from scallop,placebo,binary,39.0,169.0,35.0,167.0,,,,,,,0.1235,0.0695,0.0963,0.0423,,False,True,False,True,11096,TEST,9099
195,2096,5360580,"WMS-R (30 min) In the patients aged 77 years or younger,",1 mg/day of Pls purified from scallop,placebo,continuous,,19.0,,21.0,1.84,3.87,0.0,0.96,0.6551,0.1056,,,,,Data is from 24 weeks (final timepoint). Back calculated the SD values using CI values.,False,True,False,True,11096,TEST,9099
196,2097,5360580,WMS-R (0 min),1 mg/day of Pls purified from scallop,placebo,continuous,,24.0,,24.0,1.29,3.14,1.08,1.55,0.0834,0.0834,,,,,Data is from 28 weeks (final timepoint). Back calculated the SD values using CI values.,False,True,False,True,11096,TEST,9099
197,7734,5380284,Pain scores 48 hours after the surgery,Gum-chewing group,No gum group,continuous,,38.0,,37.0,,,,,cannot calculate,cannot calculate,,,,,,False,True,True,False,1731,TEST,1429
198,7735,5380284,Surgery duration,Gum-chewing group,No gum group,continuous,,38.0,,37.0,,,,,cannot calculate,cannot calculate,,,,,Data is unavailable.,False,False,True,False,1731,TEST,1429
199,7736,5380284,Rates of POI,Gum-chewing group,No gum group,continuous,,38.0,,37.0,,,,,cannot calculate,cannot calculate,,,,,,False,True,True,False,1731,TEST,1429
200,7737,5380284,Consumption of fentanyl,Gum-chewing group,No gum group,continuous,,38.0,,37.0,,,,,cannot calculate,cannot calculate,,,,,,False,True,True,False,1731,TEST,1429
201,7738,5380284,Pain scores 24 hours and 72 hours after the surgery,Gum-chewing group,No gum group,continuous,,38.0,,37.0,,,,,cannot calculate,cannot calculate,,,,,,False,True,True,False,1731,TEST,1429
202,5498,5380326,Interferon gamma-induced protein 10,Vitamin D supplementation,Control,continuous,,40.0,,40.0,636.47,448.47,748.88,551.0,-0.2216,0.0503,,,,,,False,True,False,True,10658,TEST,5810
203,5496,5380326,Vitamin D levels,Vitamin D supplementation,Control,continuous,,40.0,,40.0,45.93,15.37,21.87,5.31,2.0722,0.0768,,,,,,False,True,False,True,10658,TEST,5810
204,5497,5380326,Th1/Th2 cytokines,Vitamin D supplementation,Control,continuous,,40.0,,40.0,,,,,cannot calculate,cannot calculate,,,,,Unclear outcome numerical values in the RCT. Cannot clearly identify the actual metric or measure for the given outcome.,False,False,False,False,10658,TEST,5810
205,5500,5380326,Interleukin 2,Vitamin D supplementation,Control,continuous,,40.0,,40.0,4.49,13.34,28.69,103.03,-0.2276,0.0503,,,,,,False,True,False,True,10658,TEST,5810
206,5499,5380326,Dipeptidyl peptidase-4,Vitamin D supplementation,Control,continuous,,40.0,,40.0,6032.37,1359.15,6408.33,1822.17,-0.2316,0.0503,,,,,Table and text has conflicting numbers. Values are from Table.,False,False,False,True,10658,TEST,5810
207,5501,5380326,Tumor necrosis factor alpha,Vitamin D supplementation,Control,continuous,,40.0,,40.0,752.94,1890.16,548.33,1210.9,0.1277,0.0501,,,,,,False,True,False,True,10658,TEST,5810
208,2913,5459456,inflexion-extension for the C2-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8.0,,8.0,6.3,1.1,6.5,0.9,-0.1881,0.2511,,,,,,False,True,False,True,13404,TEST,7477
209,2913,5459456,inflexion-extension for the C2-C4 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8.0,,8.0,4.0,0.3,4.0,0.6,1.9928,0.3741,,,,,,False,True,False,True,13404,TEST,7477
210,2913,5459456,inflexion-extension for the C4-C5 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8.0,,8.0,1.4,0.3,1.3,0.2,0.3708,0.2543,,,,,,False,True,False,True,13404,TEST,7477
211,2913,5459456,inflexion-extension for the C5-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8.0,,8.0,1.4,0.1,1.4,0.2,0,0.25,,,,,,False,True,False,True,13404,TEST,7477
212,2913,5459456,lateral bending for the C2-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8.0,,8.0,9.2,0.9,9.6,1.1,-0.3762,0.2544,,,,,,False,True,False,True,13404,TEST,7477
213,2913,5459456,lateral bending for the C2-C4 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8.0,,8.0,5.8,0.5,5.9,0.7,-0.1554,0.2508,,,,,,False,True,False,True,13404,TEST,7477
214,2913,5459456,lateral bending for the C4-C5 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8.0,,8.0,2.0,0.4,1.8,0.2,0.5979,0.2612,,,,,,False,True,False,True,13404,TEST,7477
215,2913,5459456,lateral bending for the C5-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,continuous,,8.0,,8.0,2.2,0.4,2.0,0.3,0.5347,0.2589,,,,,,False,True,False,True,13404,TEST,7477
216,2915,5459456,new bone formation around the screws and bone-implant contact (BIC) in both sections,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating,ACVC,continuous,,8.0,,8.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,False,False,13404,TEST,7477
217,2912,5459456,surgery time,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8.0,,8.0,67.0,16.0,65.0,13.0,0.1297,0.2505,,,,,,False,True,False,True,13404,TEST,7477
218,2912,5459456,blood loss,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8.0,,8.0,56.0,19.0,51.0,20.0,0.2423,0.2518,,,,,,False,True,False,True,13404,TEST,7477
219,2912,5459456,recovery time,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8.0,,8.0,4.1,2.0,3.5,1.4,0.3286,0.2534,,,,,,False,True,False,True,13404,TEST,7477
220,2912,5459456,time before eating,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8.0,,8.0,4.5,2.2,3.9,2.3,0.6791,0.2644,,,,,,False,True,False,True,13404,TEST,7477
221,2914,5459456,Flexion-Extension stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8.0,,8.0,0.34,0.12,7.47,1.45,-6.5512,1.5912,,,,,"Data is from after fatigue test. Original outcome was just ""The stiffness"".",False,True,False,True,13404,TEST,7477
222,2914,5459456,Lateral bending stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8.0,,8.0,0.05,0.02,2.67,0.68,-5.1485,1.0784,,,,,"Data is from after fatigue test. Original outcome was just ""The stiffness"".",False,True,False,True,13404,TEST,7477
223,2914,5459456,Rotation stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),continuous,,8.0,,8.0,0.02,0.0,1.62,0.47,-4.5509,0.8972,,,,,"Data is from after fatigue test. Original outcome was just ""The stiffness"".",False,True,False,True,13404,TEST,7477
224,3486,5498715,Scores of external regulation,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,0.3,0.79,0.38,0.98,-0.0889,0.0572,,,,,,False,True,False,True,11299,DEV,5431
225,3486,5498715,Scores of amotivation,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,0.33,1.06,0.7,1.24,-0.3172,0.0579,,,,,,False,True,False,True,11299,DEV,5431
226,3487,5498715,Body mass index,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,25.78,3.3,26.53,3.53,-0.2171,0.0575,,,,,,False,True,False,True,11299,DEV,5431
227,3484,5498715,Sedentary behavior,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,5.28,2.34,5.75,2.34,-0.1986,0.0574,,,,,,False,True,False,True,11299,DEV,5431
228,3484,5498715,agility test,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,13.21,1.44,13.8,1.14,-0.4493,0.0586,,,,,Data from followup.,False,True,False,True,11299,DEV,5431
229,3483,5498715,Physical activity,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,487.33,111.47,453.57,60.87,0.3718,0.0581,,,,,,False,True,False,True,11299,DEV,5431
230,3483,5498715,physical fitness - flexibility,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,35.53,5.87,26.83,5.47,1.5165,0.0736,,,,,"Original outcome was ""physical fitness""",False,True,False,True,11299,DEV,5431
231,3483,5498715,physical fitness - muscular endurance,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,17.83,2.7,12.48,2.9,1.8883,0.0826,,,,,"Original outcome was ""physical fitness""",False,True,False,True,11299,DEV,5431
232,3483,5498715,physical fitness - agility,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,13.21,1.44,13.8,1.14,-0.4493,0.0586,,,,,"Original outcome was ""physical fitness""",False,True,False,True,11299,DEV,5431
233,3483,5498715,physical fitness - cardiorespiratory endurance,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,39.1,2.76,37.99,2.14,0.4445,0.0586,,,,,"Original outcome was ""physical fitness""",False,True,False,True,11299,DEV,5431
234,3485,5498715,Scores of intrinsic motivation,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,10.8,2.0,4.9,1.88,3.0061,0.1217,,,,,,False,True,False,True,11299,DEV,5431
235,3485,5498715,Scores of perception of competence,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,13.6,3.05,14.71,3.87,-0.3151,0.0579,,,,,,False,True,False,True,11299,DEV,5431
236,3485,5498715,Scores of perception of autonomy,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,26.6,4.43,19.89,4.56,1.4761,0.0727,,,,,,False,True,False,True,11299,DEV,5431
237,3485,5498715,Scores of enjoyment,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,27.3,6.77,26.0,4.68,0.2209,0.0575,,,,,,False,True,False,True,11299,DEV,5431
238,3485,5498715,Scores of health care climate,Motivational interviewing through self-determination theory sessions,Standard education session,continuous,,35.0,,35.0,80.5,9.97,69.89,1.59,1.4698,0.0726,,,,,,False,True,False,True,11299,DEV,5431
239,8054,5534041,composite z-scores in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12.0,,12.0,0.11,0.81,-0.25,0.71,0.4563,0.171,,,,,,False,True,False,True,6951,TEST,5679
240,8055,5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12.0,,12.0,6.0,0.9,4.8,0.9,1.2873,0.2012,,,,,,False,True,False,True,6951,TEST,5679
241,8053,5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),continuous,,12.0,,12.0,6.0,0.9,6.2,1.8,-0.1357,0.1671,,,,,,False,True,False,True,6951,TEST,5679
242,8056,5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12.0,,12.0,6.2,1.8,4.8,0.9,0.9498,0.1855,,,,,,False,True,False,True,6951,TEST,5679
243,8057,5534041,composite z-scores in autism spectrum disorder (ASD),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,continuous,,12.0,,12.0,0.13,0.82,-0.25,0.71,0.4783,0.1714,,,,,,False,True,False,True,6951,TEST,5679
244,10306,5571493,Glycemic level,Dw 5% with Quinine infusion,Dw 5% without Quinine infusion,continuous,,10.0,,10.0,0.82,0.05,0.92,0.07,-1.5744,0.262,,,,,,False,False,False,True,1507,TEST,1019
245,10307,5571493,Glycemic level,Saline + Quinine infusion,Dw 5% + Quinine infusion,continuous,,10.0,,10.0,0.74,0.05,0.82,0.05,-1.5322,0.2587,,,,,,False,False,False,True,1507,TEST,1019
246,10305,5571493,Glycemic level,Saline + Quinine infusion,Saline without Quinine infusion,continuous,,10.0,,10.0,0.74,0.05,0.83,0.05,-1.7238,0.2743,,,,,,False,False,False,True,1507,TEST,1019
247,10308,5571493,QT interval,Saline + Quinine infusion,Saline without Quinine infusion,continuous,,10.0,,10.0,,,,,cannot calculate,cannot calculate,,,,,No numerical values are given.,False,False,False,False,1507,TEST,1019
248,10309,5571493,QT interval,Dw 5%+ Quinine infusion,Dw 5% without Quinine infusion,continuous,,10.0,,10.0,,,,,cannot calculate,cannot calculate,,,,,No numerical values are given.,False,False,False,False,1507,TEST,1019
249,10310,5571493,Hypoglycemia,Saline + Quinine infusion,Saline without Quinine infusion,continuous,,10.0,,10.0,,,,,cannot calculate,cannot calculate,,,,,No numerical values are given.,False,False,False,False,1507,TEST,1019
250,12425,5614421,The incidence of respiratory distress syndrome,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,42.0,402.0,41.0,388.0,,,,,,,-0.0127,0.0539,-0.0113,0.0431,,False,True,False,True,25930,TEST,11480
251,12426,5614421,severity of any neonatal respiratory disease,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,8.0,402.0,7.0,388.0,,,,,,,0.1,0.273,0.0981,0.2628,,False,True,False,True,25930,TEST,11480
252,12427,5614421,other respiratory morbidities,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,,402.0,,388.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,,False,False,False,False,25930,TEST,11480
253,12427,5614421,"adverse infant outcomes, including serious infant composite outcome",vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,155.0,406.0,152.0,393.0,,,,,,,-0.0211,0.0212,-0.013,0.008,,False,True,False,True,25930,TEST,11480
254,12428,5614421,side effects,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,binary,134.0,394.0,118.0,382.0,,,,,,,0.1424,0.0236,0.0962,0.0108,,False,True,False,True,25930,TEST,11480
255,10572,5711682,In-stent late lumen loss at 9 months,Genoss drug-eluting stent (DES),Promus Element,continuous,,38.0,,39.0,0.11,0.25,0.16,0.43,-0.1361,0.2005,,,,,,False,True,False,True,13148,TEST,4660
256,10573,5711682,myocardial infarction (MI),Genoss drug-eluting stent (DES),Promus Element,binary,0.0,38.0,0.0,39.0,,,,,,,0.0256,4.0513,0.0253,3.9494,,False,True,False,True,13148,TEST,4660
257,10571,5711682,target lesion revascularization (TLR),Genoss drug-eluting stent (DES),Promus Element,binary,1.0,38.0,1.0,39.0,,,,,,,0.0267,2.0533,0.026,1.948,,False,True,False,True,13148,TEST,4660
258,10574,5711682,stent thrombosis,Genoss drug-eluting stent (DES),Promus Element,binary,0.0,38.0,0.0,39.0,,,,,,,0.0256,4.0513,0.0253,3.9494,,False,True,False,True,13148,TEST,4660
259,10575,5711682,rates of death,Genoss drug-eluting stent (DES),Promus Element,binary,1.0,38.0,0.0,39.0,,,,,,,1.1506,2.7186,1.1239,2.616,,False,True,False,True,13148,TEST,4660
260,13181,5771543,CGI-I response rate,fluoxetine,placebo,binary,79.0,101.0,62.0,99.0,,,,,,,0.7622,0.1013,0.2223,0.0088,,False,True,False,True,12534,DEV,9831
261,13182,5771543,CGI-I response rate,desvenlafaxine,placebo,binary,68.0,99.0,62.0,99.0,,,,,,,0.2693,0.0901,0.0924,0.0106,,False,True,False,True,12534,DEV,9831
262,13183,5771543,Treatment-emergent adverse events (TEAEs),desvenlafaxine,placebo,binary,69.0,115.0,79.0,112.0,,,,,,,-0.4675,0.0792,-0.1618,0.0095,,False,True,False,True,12534,DEV,9831
263,13183,5771543,Treatment-emergent adverse events (TEAEs),fluoxetine,placebo,binary,72.0,112.0,79.0,112.0,,,,,,,-0.2852,0.0819,-0.0928,0.0087,Typo in the table,False,True,False,True,12534,DEV,9831
264,2786,2430617,HBeAg sero-conversion rate,60 µg of immune complexes (YIC),placebo,binary,17.0,80.0,7.0,79.0,,,,,,,1.0208,0.2314,0.8747,0.1765,effects found in abstract and exact number in results table,False,True,False,True,7987,TEST,4896
265,2787,2430617,adverse events,30 µg YIC,placebo,binary,,,,,,,,,,,,,,,,False,True,False,True,7987,TEST,4896
266,2787,2430617,adverse events,60 µg of YIC,placebo,binary,7.0,163.0,4.0,79.0,,,,,,,-0.1728,0.4126,-0.1647,0.3741,effects found in abstract and number of samples in text,False,False,False,True,7987,TEST,4896
267,12440,2596788,GERD-knowledge,education,control,continuous,,102.0,,109.0,,,,,cannot calculate,cannot calculate,,,,,no standard deviations given or mean differences,True,False,False,False,5143,TEST,3554
268,2991,3214395,laryngoscopy duration,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 45",group 3 involved bispectral index (BIS) of 35,continuous,,60.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,mean and std not given for group 1 and 2 combined,False,True,True,False,1201,TEST,996
269,2991,3214395,laryngospasm,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 46",group 3 involved bispectral index (BIS) of 36,binary,11.0,60.0,3.0,30.0,,,,,,,0.7033,0.4817,0.6061,0.3742,,False,True,True,True,1201,TEST,996
270,2991,3214395,bronchospasm,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 47",group 3 involved bispectral index (BIS) of 37,binary,1.0,60.0,0.0,30.0,,,,,,,0.4304,2.7163,0.4217,2.618,,False,True,True,True,1201,TEST,996
271,2991,3214395,laryngoscopy failure,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 48",group 3 involved bispectral index (BIS) of 38,continuous,,60.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,mean and std not given for group 1 and 2 combined,False,True,True,False,1201,TEST,996
272,2991,3214395,extremity movement,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 49",group 3 involved bispectral index (BIS) of 39,binary,16.0,60.0,9.0,30.0,,,,,,,-0.1643,0.244,-0.1178,0.1236,,False,True,True,True,1201,TEST,996
273,2991,3214395,awakening,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 50",group 3 involved bispectral index (BIS) of 40,continuous,,60.0,,30.0,,,,,cannot calculate,cannot calculate,,,,,mean and std not given for group 1 and 2 combined,False,True,True,False,1201,TEST,996
274,6419,3654355,Body weight,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,-17.5,6.1,-0.5,2.8,-3.1892,0.0933,,,,,,False,True,False,True,18948,TEST,9604
275,6420,3654355,Fat mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,-15.7,5.3,-0.4,5.0,-2.9163,0.0853,,,,,,False,True,False,True,18948,TEST,9604
276,6421,3654355,Visceral fat,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,-82.3,31.6,4.3,22.7,-2.6604,0.0784,,,,,,False,True,False,True,18948,TEST,9604
277,6422,3654355,Baseline Height,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,173.2,8.6,172.3,10.4,0.0971,0.0444,,,,,,False,True,False,True,18948,TEST,9604
278,6422,3654355,Baseline body mass index,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,42.8,4.6,42.8,6.3,0,0.0444,,,,,,False,True,False,True,18948,TEST,9604
279,6422,3654355,baseline body weight,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,128.9,19.4,127.1,21.6,0.0888,0.0444,,,,,,False,True,False,True,18948,TEST,9604
280,6422,3654355,baseline fat mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,60.5,11.0,60.4,13.5,0.0084,0.0444,,,,,,False,True,False,True,18948,TEST,9604
281,6422,3654355,baseline fat-free mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,68.3,13.2,67.1,12.8,0.0911,0.0444,,,,,,False,True,False,True,18948,TEST,9604
282,6422,3654355,baseline skeletal muscle mass,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,38.4,7.9,37.9,7.4,0.0641,0.0444,,,,,,False,True,False,True,18948,TEST,9604
283,6422,3654355,baseline visceral fat area,Intensive lifestyle intervention (ILI) group,Waiting list control,continuous,,71.0,,33.0,255.7,64.7,245.6,66.3,0.1538,0.0445,,,,,,False,True,False,True,18948,TEST,9604
284,6301,3929816,Baseline characteristics and general anesthesia procedure,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,continuous,,10.0,,10.0,,,,,cannot calculate,cannot calculate,,,,,No quantitative measures given,False,False,False,False,1047,TEST,859
285,6302,3929816,Pathologic changes in the liver,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,continuous,,10.0,,10.0,,,,,cannot calculate,cannot calculate,,,,,No quantitative measures given,False,False,False,False,1047,TEST,859
286,6303,3929816,Pathologic changes in the kidneys,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,continuous,,10.0,,10.0,20.0,,,,cannot calculate,cannot calculate,,,,,Not enough measures given for calculation,False,False,False,False,1047,TEST,859
287,6100,4215531,alpha power,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,,,,,cannot calculate,cannot calculate,,,,,"F-values given, not sure how to use them",False,False,False,False,7350,TEST,5561
288,6102,4215531,alpha power,facial affect training (FAT) in 20 daily 1-hour sessions,treatment as usual (TAU),continuous,,19.0,,19.0,,,,,cannot calculate,cannot calculate,,,,,"F-values given, not sure how to use them",False,False,False,False,7350,TEST,5561
289,6103,4215531,MCCB performance : Processing Speed,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,44.6,12.2,48.2,12.3,-0.2877,0.1064,,,,,used post values and Treatment as Usual as Baseline,False,True,False,True,7350,TEST,5561
290,6103,4215531,MCCB performance : Attentional Vigilance,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,38.5,11.8,41.3,10.1,-0.2496,0.1061,,,,,used post values and Treatment as Usual as Baseline,False,True,False,True,7350,TEST,5561
291,6103,4215531,MCCB performance : Visual Learning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,49.4,12.8,46.5,9.8,0.2491,0.1061,,,,,used post values and Treatment as Usual as Baseline,False,True,False,True,7350,TEST,5561
292,6104,4215531,MCCB performance : Working Memory,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,48.2,9.2,50.8,12.1,-0.2368,0.106,,,,,used post values and Treatment as Usual as Baseline,False,True,False,True,7351,TEST,5561
293,6104,4215531,MCCB performance : Verbal Learning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,47.1,10.0,47.3,10.4,-0.0192,0.1053,,,,,used post values and Treatment as Usual as Baseline,False,True,False,True,7352,TEST,5561
294,6104,4215531,MCCB performance : Reasoning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,47.9,8.8,46.5,9.8,0.1472,0.1055,,,,,used post values and Treatment as Usual as Baseline,False,True,False,True,7353,TEST,5561
295,6104,4215531,MCCB performance : Social Cognition,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,continuous,,19.0,,19.0,39.3,11.1,42.8,11.7,-0.3005,0.1065,,,,,used post values and Treatment as Usual as Baseline,False,False,False,False,7350,TEST,5561
296,5595,4355974,Days of wheeze,BostonBreathes system,Control,continuous,,28.0,,14.0,-1.4,,-4.2,,,,,,,,standard deviations not given and means are mean change,False,True,False,False,7450,TEST,5464
297,5596,4355974,ER visits,BostonBreathes system,Control,binary,1.0,28.0,1.0,14.0,,,,,,,-0.7309,2.114,-0.6931,1.8929,found in table,False,True,False,True,7450,TEST,5464
298,5597,4355974,Days limited activity from asthma,BostonBreathes system,Control,continuous,,28.0,,14.0,-0.2,,-1.8,,cannot calculate,cannot calculate,,,,,"standard deviations not given, means are mean change",False,True,False,False,7450,TEST,5464
299,5598,4355974,Knowledge,BostonBreathes system,Control,binary,9.0,12.0,3.0,8.0,,,,,,,1.6094,0.9778,0.6931,0.2361,"found in table,",False,True,False,True,7450,TEST,5464
300,5599,4355974,School days missed for asthma,BostonBreathes system,Control,continuous,,28.0,,14.0,-0.2,,-0.4,,cannot calculate,cannot calculate,,,,,"standard deviations not given, means are mean change",False,True,False,False,7450,TEST,5464
301,5600,4355974,Days patient had to slow down,BostonBreathes system,Control,continuous,,28.0,,14.0,-1.4,,-0.4,,cannot calculate,cannot calculate,,,,,"standard deviations not given, means are mean change",False,True,False,False,7450,TEST,5464
302,3878,4357072,improvement in symptom scores,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,continuous,,15.0,,15.0,0.2,0.4,0.8,0.6,-1.1448,0.1552,,,,,significance found in abstract and numbers in results,False,True,True,True,2097,TEST,1624
303,3879,4357072,reduction in burning sensation,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,continuous,,15.0,,15.0,1.0,2.1,5.3,6.1,-0.9171,0.1474,,,,,significance found in abstract and numbers in results,False,True,True,True,2097,TEST,1624
304,3880,4357072,reduction in erythematous area,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,binary,14.0,15.0,10.0,15.0,,,,,,,1.9459,1.3714,0.3365,0.0381,significance found in abstract and numbers in results,False,True,True,True,2097,TEST,1624
305,3882,4357072,reappearance of erythematous areas after 2 months posttreatment,pimecrolimus,triamcinolone acetate,binary,1.0,15.0,5.0,15.0,,,,,,,-1.9459,1.3714,-1.6094,1.0667,significance found in abstract and numbers in results,False,True,False,True,2097,TEST,1624
306,7831,4541185,duration of sensory block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30.0,,30.0,703.83,42.9,556.38,37.96,3.5929,0.1742,,,,,found in text,False,True,True,True,1359,TEST,1043
307,7831,4541185,duration of motor block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30.0,,30.0,621.67,46.76,500.86,44.58,2.6102,0.1234,,,,,found in text,False,True,True,True,1359,TEST,1043
308,7832,4541185,duration of analgesia,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30.0,,30.0,878.33,89.955,613.1,51.797,2.7597,0.1301,,,,,found in text,False,True,True,True,1359,TEST,1043
309,7833,4541185,onset of sensory block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30.0,,30.0,4.36,0.81,4.84,0.65,-0.6451,0.0701,,,,,found in abstract,False,False,False,True,1359,TEST,1043
310,7833,4541185,onset of motor block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30.0,,30.0,9.83,1.12,10.85,0.79,-1.0388,0.0757,,,,,found in abstract,False,False,False,True,1359,TEST,1043
311,7834,4541185,drop in heart rate,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30.0,,30.0,76.1,8.91,76.77,8.76,-0.0748,0.0667,,,,,found in table,False,True,True,True,1359,TEST,1043
312,7835,4541185,drop in mean arterial pressure,ropivacaine + diluted clonidine with saline,ropivacaine + saline,continuous,,30.0,,30.0,91.2,6.62,92.04,7.15,-0.1203,0.0668,,,,,found in table,False,True,True,True,1359,TEST,1043
313,9840,4928400,Stone-free rate,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,binary,22.0,22.0,16.0,20.0,,,,,,,2.5074,2.3273,0.2192,0.014,,False,True,False,True,4037,TEST,2288
314,9841,4928400,Operative time,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22.0,,20.0,74.1,12.2,78.0,6.4,-0.3985,0.0973,,,,,found in table,False,True,False,True,4037,TEST,2288
315,9842,4928400,Complication,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,binary,5.0,22.0,7.0,20.0,,,,,,,-0.6047,0.4786,-0.4318,0.2474,,False,True,False,True,4037,TEST,2288
316,9843,4928400,Postoperative pain,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22.0,,20.0,4.3,1.0,3.6,1.2,0.619,0.1,,,,,,False,True,False,True,4037,TEST,2288
317,9844,4928400,Hospital stay,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22.0,,20.0,4.2,1.2,2.1,1.1,1.7938,0.1338,,,,,,False,True,False,True,4037,TEST,2288
318,9845,4928400,Time for return to daily activities,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,continuous,,22.0,,20.0,13.3,1.7,9.0,1.6,2.5595,0.1734,,,,,,False,True,False,True,4037,TEST,2288
319,4723,5539943,reflections of sustain talk,Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,False,False,False,False,9850,TEST,5076
320,4724,5539943,"""sustain talk"" (ST)",Language Enhanced Attention and Focus MI training condition (MI-LEAF),baseline,continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,False,False,False,False,9850,TEST,5076
321,4725,5539943,"Frequency of client ""change talk"" (CT)",Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,False,False,False,False,9850,TEST,5076
322,4726,5539943,Motivational Interviewing (MI) knowledge,Language Enhanced Attention and Focus MI training condition (MI-LEAF),baseline,continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,False,False,False,False,9850,TEST,5076
323,4726,5539943,Motivational Interviewing (MI) knowledge,MI training (MI-AU),baseline,continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,False,False,False,False,9850,TEST,5076
324,4727,5539943,Motivational Interviewing (MI) knowledge,Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,False,False,False,False,9850,TEST,5076
325,5372,5559992,Anxiety,Buprenophine 32 mg,No treatment,continuous,,5.0,,5.0,1.0,2.23,11.0,8.63,-1.4322,0.5026,,,,,"decided ""no treatment"" meant baseline",False,True,True,True,1146,TEST,884
326,5373,5559992,Anxiety,Buprenophine 64 mg,No treatment,continuous,,4.0,,4.0,1.25,2.5,26.5,14.7,-2.0802,0.7704,,,,,"decided ""no treatment"" meant baseline",False,True,True,True,1146,TEST,884
327,5374,5559992,Anxiety,Buprenophine 96 mg,No treatment,continuous,,5.0,,5.0,0.0,0.0,23.8,13.82,-2.1985,0.6417,,,,,"decided ""no treatment"" meant baseline",False,True,True,True,1146,TEST,884
328,5375,5559992,Anxiety,Buprenophine 32 mg,Buprenophine 64 mg,continuous,,5.0,,4.0,1.0,2.23,1.25,2.5,-0.0945,0.4505,,,,,found in table,False,True,True,True,1146,TEST,884
329,5376,5559992,Anxiety,Buprenophine 32 mg,Buprenophine 96 mg,continuous,,5.0,,5.0,1.0,2.23,0.0,0.0,0.5725,0.4164,,,,,found in table,False,True,True,True,1146,TEST,884
330,5377,5559992,Anxiety,Buprenophine 64 mg,Buprenophine 96 mg,continuous,,4.0,,5.0,1.25,2.5,0.0,0.0,0.6784,0.4756,,,,,found in table,False,True,True,True,1146,TEST,884
331,5078,5617873,Parent-rated Aberrant Behavior Checklis improvement,Aripiprazole,Placbeo,continuous,,45.0,,47.0,-11.4,1.3,-7.5,1.4,-2.8604,0.088,,,,,"all means and std found in table 2, given as mean change from baseline",False,True,False,True,7551,TEST,5383
332,5079,5617873,Clinician-rated Clinical Global Impression-Improvement scores,Aripiprazole,Placbeo,continuous,,,,,2.4,0.1,3.4,0.1,-9.9164,0.5779,,,,,raw values foun din text,False,False,False,True,7551,TEST,5383
333,5080,5617873,Serious adverse effects,Aripiprazole,Placbeo,binary,0.0,45.0,3.0,47.0,,,,,,,-1.9681,2.3302,-1.9034,2.2431,all means and std found in table 2,False,True,False,True,7551,TEST,5383
334,5081,5617873,Inappropriate speech,Aripiprazole,Placbeo,continuous,,45.0,,47.0,-2.2,0.4,-1.5,0.4,-1.7354,0.0599,,,,,"table 2, given as mean change",False,True,False,True,7551,TEST,5383
335,5082,5617873,Social withdrawal,Aripiprazole,Placbeo,continuous,,45.0,,47.0,-4.7,1.1,-5.2,1.0,0.4722,0.0447,,,,,"table 2, given as mean change",False,True,False,True,7551,TEST,5383
336,5083,5617873,Compulsion scale,Aripiprazole,Placbeo,continuous,,45.0,,47.0,-1.3,0.5,-2.0,0.5,1.3883,0.054,,,,,"table 2, given as mean change",False,True,False,True,7551,TEST,5383
337,11078,5655920,Nausea,Lixisenatide with normal renal function,Lixisenatide with mild impairment,binary,,2094.0,,637.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = -0.1,False,True,False,True,13081,TEST,5825
338,11078,5655920,vomiting,Lixisenatide with normal renal function,Lixisenatide with mild impairment,binary,,2094.0,,637.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = -0.1,False,True,False,True,13081,TEST,5825
339,11079,5655920,Nausea,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,binary,,122.0,,637.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = 0.04,False,True,False,True,13081,TEST,5825
340,11079,5655920,vomiting,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,binary,,122.0,,637.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = 0.04,False,True,False,True,13081,TEST,5825
341,11080,5655920,Nausea,Lixisenatide with moderate impairment,Lixisenatide with normal renal function,binary,,122.0,,2094.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = -0.03,False,True,False,True,13081,TEST,5825
342,11080,5655920,vomiting,Lixisenatide with moderate impairment,Lixisenatide with normal renal function,binary,,122.0,,2094.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = -0.03,False,True,False,True,13081,TEST,5825
343,11081,5655920,Hypoglycaemia,Lixisenatide with normal renal function,Lixisenatide with mild impairment,binary,,2094.0,,637.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = -0.02,False,True,False,True,13081,TEST,5825
344,11082,5655920,Hypoglycaemia,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,binary,,122.0,,637.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = 0.04,False,True,False,True,13081,TEST,5825
345,10232,5686687,Pain,Resveratrol,Placebo,continuous,,22.0,,22.0,,,,,cannot calculate,cannot calculate,,,,,given as median and range,False,True,False,False,7451,TEST,3515
346,10233,5686687,Need for dipyrone,Resveratrol,Placebo,continuous,,22.0,,22.0,1944.0,1793.0,625.0,250.0,1.0119,0.1025,,,,,found in table,False,True,False,True,7451,TEST,3515
347,10234,5686687,Need for Ibuprofen,Resveratrol,Placebo,continuous,,22.0,,22.0,1200.0,848.0,5640.0,328.0,-6.7818,0.6136,,,,,found in table,False,True,False,True,7451,TEST,3515
348,10235,5686687,Prolactin levels,Resveratrol,Placebo,continuous,,22.0,,22.0,,,,,cannot calculate,cannot calculate,,,,,median and ranges given,False,True,False,False,7451,TEST,3515
349,10236,5686687,CA-125 levels,Resveratrol,Placebo,continuous,,22.0,,22.0,,,,,cannot calculate,cannot calculate,,,,,median and ranges given,False,True,False,False,7451,TEST,3515
350,4493,5874317,Knee extension (1-rep Max),Bilateral training,Unilateral training,continuous,,9.0,,9.0,237.2,51.0,182.4,8.4,1.4252,0.2786,,,,,Found in table raw values,False,True,False,True,10785,TEST,5696
351,4494,5874317,Knee flexion (1-rep Max),Bilateral training,Unilateral training,continuous,,9.0,,9.0,99.8,10.2,86.8,2.9,1.6509,0.2979,,,,,Found in table raw values,False,True,False,True,10785,TEST,5696
352,4495,5874317,Change of direction improvement,Bilateral training,Unilateral training,continuous,,9.0,,9.0,5.46,0.2,5.67,0.16,-1.1042,0.2561,,,,,Found in table raw values,False,True,False,True,10785,TEST,5696
353,4496,5874317,Squat jump,Bilateral training,Unilateral training,continuous,,9.0,,9.0,0.37,0.04,0.34,0.04,0.7142,0.2364,,,,,Found in table raw values,False,True,False,True,10785,TEST,5696
354,4497,5874317,Horizontal countermovement jump,Bilateral training,Unilateral training,continuous,,9.0,,9.0,2.34,0.07,2.21,0.15,1.0576,0.2533,,,,,Found in table raw values,False,True,False,True,10785,TEST,5696
355,4498,5874317,Horizontal triple jump (non-dominant leg),Bilateral training,Unilateral training,continuous,,9.0,,9.0,5.71,0.71,5.7,0.45,0.016,0.2222,,,,,Found in table raw values,False,True,False,True,10785,TEST,5696
356,4710,5884950,objective-SCORAD score,extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,continuous,,13.0,,13.0,,,,,cannot calculate,cannot calculate,,,,,"mean and std not given, only median and interquartile range",False,False,False,False,11712,TEST,6635
357,4711,5884950,chemokines CXCL9,extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,continuous,,13.0,,13.0,,,,,cannot calculate,cannot calculate,,,,,"mean and std not given, only median and interquartile range",False,False,False,False,11712,TEST,6635
358,8710,5971365,clinically meaningful improvement at week 144 (⩾3-point increase on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,binary,188.0,287.0,144.0,277.0,,,,,,,0.5619,0.0299,0.2312,0.0052,"counts calculated from percentages given in text, totals found in figure",False,False,False,True,3177,TEST,2394
359,8711,5971365,Symbol Digit Modalities Test (SDMT) score at week 96,daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,continuous,,720.0,,682.0,4.1,12.4,2.9,12.7,0.0956,0.0029,,,,,"found in figure and text, totals found in figure",True,False,False,True,3177,TEST,2394
360,8712,5971365,Symbol Digit Modalities Test (SDMT) score at week 144 in limited patients,daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,continuous,,287.0,,277.0,6.3,12.6,3.1,13.2,0.2478,0.0071,,,,,"found in figure and text, totals found in figure",False,False,False,True,3177,TEST,2394
361,8713,5971365,clinically meaningful worsening at week 96 (⩾3-point decrease on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,binary,140.0,720.0,169.0,682.0,,,,,,,-0.311,0.0167,-0.2425,0.0102,"counts calculated from percentages given in text, totals found in figure",True,False,False,True,3177,TEST,2394
362,8714,5971365,clinically meaningful improvement at week 96 (⩾3-point increase on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,binary,432.0,720.0,369.0,682.0,,,,,,,0.2409,0.0117,0.1034,0.0022,"counts calculated from percentages given in text, totals found in figure",True,False,False,True,3177,TEST,2394
363,12884,5976949,ANGPTL4 expression,"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)",control group- normal glucose tolerance,continuous,,20.0,,25.0,23.1,25.6,98.3,104.6,-0.9238,0.0995,,,,,found in table,False,True,False,True,4402,TEST,2905
364,12885,5976949,ANGPTL4 expression,"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)","GDM2 (less tight glycaemic targets, <5.3_mmol/L and <_7.8_mmol/L)",continuous,,20.0,,21.0,23.1,25.6,21.5,25.8,0.061,0.0977,,,,,found in table,False,True,False,True,4402,TEST,2905
365,12886,5976949,leptin/adiponectin ratio (LAR),"GDM2 (less tight glycaemic targets, <5.3 mmol/L and < 7.8 mmol/L)","GDM1 (tight glycaemic targets, fasting blood glucose_<_5.1_mmol/L and <7.0_mmol/L postprandial) postprandial,), control group- normal glucose tolerance",continuous,,21.0,,45.0,1.7,1.66,,,cannot calculate,cannot calculate,,,,,combined means and stds not given,False,True,False,False,4402,TEST,2905
366,12887,5976949,leptin/adiponectin ratio (LAR),"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)",control group- normal glucose tolerance,continuous,,20.0,,25.0,0.97,1.31,0.72,0.46,0.2624,0.0908,,,,,found in table,False,True,False,True,4402,TEST,2905
367,224,1475568,Minnesota living with heart failure (MLHF) questionnaire baseline scores,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59.0,,64.0,45.0,,57.0,,cannot calculate,cannot calculate,,,,,Only the mean score was given in table.,False,True,False,False,4361,TEST,3649
368,216,1475568,Heart failure-related quality of life at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59.0,,64.0,1.0,,5.0,,cannot calculate,cannot calculate,,,,,Only the mean change was found in text.,False,False,False,False,4361,TEST,3649
369,217,1475568,Baseline hypertension,Follow-up and thorough education on self-care,Standard information about self-care,binary,51.0,59.0,57.0,64.0,,,,,,,-0.2448,0.305,-0.0299,0.0046,Used percentage found in table to calculate actual number for binary variable.,False,True,False,True,4361,TEST,3649
370,218,1475568,Baseline diabetes,Follow-up and thorough education on self-care,Standard information about self-care,binary,35.0,59.0,33.0,64.0,,,,,,,0.3148,0.1328,0.1402,0.0263,Used percentage found in table to calculate actual number for binary variable.,False,True,False,True,4361,TEST,3649
371,228,1475568,Baseline life-quality score,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59.0,,64.0,45.0,,57.0,,cannot calculate,cannot calculate,,,,,Only the mean score was given in table.,False,True,False,False,4361,TEST,3649
372,226,1475568,Knowledge about heart failure,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59.0,,64.0,,,,,cannot calculate,cannot calculate,,,,,Only the overall mean difference in score improvement was given.,False,False,False,False,4361,TEST,3649
373,220,1475568,Baseline beta-blockers intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,32.0,59.0,46.0,64.0,,,,,,,-0.7684,0.1456,-0.2816,0.0204,Used percentage found in table to calculate actual number for binary variable.,False,True,False,True,4361,TEST,3649
374,227,1475568,Self-efficacy,Follow-up and thorough education on self-care,Standard information about self-care,continuous,,59.0,,64.0,,,,,cannot calculate,cannot calculate,,,,,Only the overall mean difference in score improvement was given.,False,False,False,False,4361,TEST,3649
375,219,1475568,Baseline systolic dysfunction,Follow-up and thorough education on self-care,Standard information about self-care,binary,23.0,59.0,28.0,64.0,,,,,,,-0.1967,0.1347,-0.1154,0.0466,Used percentage found in table to calculate actual number for binary variable.,False,True,False,True,4361,TEST,3649
376,223,1475568,Baseline angiotensin II receptor blockers (ARBs) intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,,59.0,,64.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Unclear since the values for this are reported with ACEI intake.,False,True,False,False,4361,TEST,3649
377,222,1475568,Baseline digoxin intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,15.0,59.0,12.0,64.0,,,,,,,0.3902,0.192,0.3045,0.1174,Used percentage found in table to calculate actual number for binary variable.,False,True,False,True,4361,TEST,3649
378,221,1475568,Baseline angiotensin-converting enzyme (ACE) inhibitors intake,Follow-up and thorough education on self-care,Standard information about self-care,binary,,59.0,,64.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Unclear since the values for this are reported with ARB intake.,False,True,False,False,4361,TEST,3649
379,214,1475568,Hospitalization or death,Follow-up and thorough education on self-care,Standard information about self-care,binary,25.0,59.0,39.0,64.0,,,,,,,-0.7522,0.1351,-0.3633,0.0331,Used percentage found in table to calculate actual number for binary variable.,False,True,False,True,4361,TEST,3649
380,215,1475568,Daily weight monitoring at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,binary,47.0,59.0,19.0,64.0,,,,,,,2.2275,0.1795,0.9871,0.0413,Used percentage found in text to calculate actual number for binary variable.,False,False,False,True,4361,TEST,3649
381,225,1475568,Cardiac-related hospitalization,Follow-up and thorough education on self-care,Standard information about self-care,binary,20.0,59.0,25.0,64.0,,,,,,,-0.2231,0.1413,-0.1418,0.0574,Used percentage found in text to calculate actual number for binary variable.,False,False,False,True,4361,TEST,3649
382,876,2974815,discontinued treatment,"""phone calls"" group","""no phone calls"" group",binary,4.0,108.0,30.0,246.0,,,,,,,-1.284,0.2976,-1.1917,0.27,Values from results section text.,False,False,False,True,13659,TEST,6016
383,949,3278655,maximum total point motion (MTPM),The trabecular metal tibial monoblock component (TM),cemented component.,continuous,,27.0,,18.0,0.98,3.91,0.79,2.27,0.0556,0.0926,,,,,Back calculated the SD values from CI. Numerical values are from 5-year follow up.,False,True,False,True,5463,TEST,3510
384,877,2974815,The percentage of patients with controlled blood pressure (<140/90 mmHg),"""phone calls"" group","""no phone calls"" group",binary,,108.0,,246.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Numerical values are not available.,False,False,False,False,13659,TEST,6016
385,1118,3577738,website use in terms of the number of pages visited,website with social presence elements.,website without social presence elements.,continuous,,,,,7.5,4.0,8.0,3.8,cannot calculate,cannot calculate,,,,,Cannot find the group sizes in the text or table.,False,True,False,False,3018,TEST,2080
386,1118,3577738,website use in terms of time on the website,website with social presence elements.,website without social presence elements.,continuous,,,,,151.0,117.4,150.8,107.8,cannot calculate,cannot calculate,,,,,Cannot find the group sizes in the text or table.,False,True,False,False,3018,TEST,2080
387,1119,3577738,focused on the social presence elements in terms of frequency,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",False,False,False,False,3018,TEST,2080
388,1119,3577738,focused on the social presence elements in terms of duration,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",False,False,False,False,3018,TEST,2080
389,875,2974815,percentage of patients with controlled blood pressure,"""phone calls"" group","""no phone calls"" group",binary,86.0,108.0,175.0,246.0,,,,,,,0.4612,0.0769,0.1128,0.004,"Used 80% for ""phone calls"" group and 71% for ""no phone calls"" group.",False,False,False,True,13659,TEST,6016
390,950,3278655,subsidence,The trabecular metal tibial monoblock component (TM),cemented component.,continuous,,27.0,,18.0,-0.38,0.37,-0.04,0.11,-1.1288,0.1068,,,,,Used numerical values for Superior/inferior translation (SD). Numerical values are from 5-year follow up.,False,True,False,True,5463,TEST,3510
391,951,3278655,"The proportion of ""at risk"" components at 5 years",The trabecular metal tibial monoblock component (TM),cemented component.,binary,0.0,27.0,2.0,18.0,,,,,,,-2.1203,2.497,-1.9972,2.3117,Used numerical values from 5-year follow up provided in abstract.,False,False,False,True,5463,TEST,3510
392,1120,3577738,efficiency,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",False,False,False,False,3018,TEST,2080
393,1120,3577738,effectiveness,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",False,False,False,False,3018,TEST,2080
394,1120,3577738,enjoyment,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",False,False,False,False,3018,TEST,2080
395,1120,3577738,active trust,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",False,False,False,False,3018,TEST,2080
396,1120,3577738,interest,website with social presence elements.,website without social presence elements.,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",False,False,False,False,3018,TEST,2080
397,2240,4678179,progression-free-survival (PFS),vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),continuous,,53.0,,53.0,,,,,cannot calculate,cannot calculate,,,,,Median was only given.,False,False,False,False,9517,TEST,6474
398,2241,4678179,Median overall survival (OS),vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),continuous,,53.0,,53.0,6.9,4.09,6.1,5.57,0.1625371,0.03786046,,,,,"Median is given with CI. Since the outcome explicitly says ""median"", including median values. Back calculated SD using CI.",False,False,False,True,9517,TEST,6474
399,2242,4678179,Response rates,vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),continuous,,53.0,,53.0,8.0,,13.0,,cannot calculate,cannot calculate,,,,,Only difference in response rates as percent is given.,False,False,False,False,9517,TEST,6474
400,2243,4678179,rate of adverse events,vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),binary,4.0,53.0,2.0,53.0,,,,,,,0.73315252,0.79001601,0.69314718,0.71226415,Used numbers found in results section text.,False,False,False,True,9517,TEST,6474
401,2723,5268424,score on the general dimension scale of negative affects (referred to as NA from here onward),view a video featuring individuals that live in extreme poverty,control,continuous,,55.0,,50.0,21.036,6.327,17.68,5.859,0.5453569,0.03959808,,,,,,False,True,False,True,12258,TEST,6615
402,2804,5781260,Exercise-induced Creatine kinase (CK),lemon verbena extract,placebo,continuous,,20.0,,20.0,,,,,cannot calculate,cannot calculate,,,,,Mean and CI in figure.,True,False,False,False,4385,TEST,3505
403,2802,5781260,exercise-related loss of muscle strength,lemon verbena extract,placebo,continuous,,20.0,,20.0,,,,,cannot calculate,cannot calculate,,,,,Mean and CI in figure.,True,False,False,False,4385,TEST,3505
404,2805,5781260,Glutathione peroxidase (GPxP),lemon verbena extract,placebo,continuous,,20.0,,20.0,,,,,cannot calculate,cannot calculate,,,,,Mean and CI in figure.,True,False,False,False,4385,TEST,3505
405,2807,5781260,adverse events,lemon verbena extract,placebo,binary,,20.0,,20.0,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Unclear numerical values.,False,False,False,False,4385,TEST,3505
406,2803,5781260,Movement induced pain (VAS),lemon verbena extract,placebo,continuous,,20.0,,20.0,,,,,cannot calculate,cannot calculate,,,,,Mean and CI in figure.,False,False,False,False,4385,TEST,3505
407,2806,5781260,Interleukin 6,lemon verbena extract,placebo,continuous,,20.0,,20.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values are not given.,False,False,False,False,4385,TEST,3505
408,3260,3475525,Correct selection of the healthier product,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,73.3,6.9,67.8,10.3,0.61923041,0.02222653,,,,,Available in abstract and table,False,True,False,True,9086,TEST,4934
409,3260,3475525,Correct selection of the healthier product,MTL+caloric intake group,TL+SNL group,continuous,,90.0,,95.0,73.3,6.9,65.8,7.3,1.05077696,0.02462157,,,,,Available in abstract and table,False,True,False,True,9086,TEST,4934
410,3260,3475525,Correct selection of the healthier product,choices group,No label group,continuous,,98.0,,99.0,72.5,13.2,67.8,10.3,0.3957062,0.02070251,,,,,Available in abstract and table,False,True,False,True,9086,TEST,4934
411,3260,3475525,Correct selection of the healthier product,choices group,TL+SNL group,continuous,,98.0,,95.0,72.5,13.2,65.8,7.3,0.62309408,0.02173622,,,,,Available in abstract and table,False,True,False,True,9086,TEST,4934
412,3262,3475525,Taste perception,MTL group,No label group,continuous,,98.0,,99.0,5.6,1.4,5.8,1.4,-0.1423069,0.02035649,,,,,,False,True,False,True,9086,TEST,4934
413,3262,3475525,Taste perception,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,5.4,1.4,5.8,1.4,-0.2845666,0.02142635,,,,,,False,True,False,True,9086,TEST,4934
414,3262,3475525,Taste perception,MTL group,choices group,continuous,,98.0,,98.0,5.6,1.4,5.3,1.5,0.20597307,0.02051639,,,,,,False,True,False,True,9086,TEST,4934
415,3262,3475525,Taste perception,MTL+caloric intake group,choices group,continuous,,90.0,,98.0,5.4,1.4,5.3,1.5,0.06854473,0.02132769,,,,,,False,True,False,True,9086,TEST,4934
416,3262,3475525,intent of purchase,MTL group,No label group,continuous,,98.0,,99.0,3.8,1.4,4.1,1.5,-0.2059408,0.02041274,,,,,Used values for self.,False,True,False,True,9086,TEST,4934
417,3262,3475525,intent of purchase,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,3.6,1.4,4.1,1.5,-0.3426709,0.02152276,,,,,Used values for self.,False,True,False,True,9086,TEST,4934
418,3262,3475525,intent of purchase,MTL group,choices group,continuous,,98.0,,98.0,3.8,1.4,4.1,1.7,-0.1919025,0.02050211,,,,,Used values for self.,False,True,False,True,9086,TEST,4934
419,3262,3475525,intent of purchase,MTL+caloric intake group,choices group,continuous,,90.0,,98.0,3.6,1.5,4.1,1.7,-0.3098034,0.02157045,,,,,Used values for self.,False,True,False,True,9086,TEST,4934
420,3401,3877023,quantitative contour sharpness of the Cervicothoracic Spine,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,18.0,,21.0,0.95,0.24,1.43,0.48,-1.2099846,0.12194464,,,,,"Original outcome was ""quantitative contour sharpness"".",False,False,False,True,17694,TEST,9686
421,3401,3877023,quantitative contour sharpness of the thoracolumbar spine,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,30.0,,34.0,0.83,0.22,1.32,0.51,-1.2060514,0.07410885,,,,,"Original outcome was ""quantitative contour sharpness"".",False,False,False,True,17694,TEST,9686
422,3402,3877023,contrast-to-noise ratios (CNR) of Cervicothoracic Spine - T2w sagittal Cerebrospinal fluid – Spinal cord,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,18.0,,21.0,18.1,11.6,9.3,5.5,0.97494517,0.11536073,,,,,,False,True,False,True,17694,TEST,9686
423,3402,3877023,contrast-to-noise ratios (CNR) of Thoracolumbar Spine - T2w sagittal Cerebrospinal fluid – Spinal cord,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,30.0,,34.0,22.3,13.2,14.0,5.6,0.8274306,0.06809386,,,,,,False,True,False,True,17694,TEST,9686
424,3402,3877023,contrast-to-noise ratios (CNR) of Cervicothoracic Spine - T2w sagittal Cerebrospinal fluid – Vertebral bone,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,18.0,,21.0,19.3,10.3,8.2,5.7,1.33530568,0.12603411,,,,,,False,True,False,True,17694,TEST,9686
425,3402,3877023,contrast-to-noise ratios (CNR) of Thoracolumbar Spine - T2w sagittal Cerebrospinal fluid – Vertebral bone,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,30.0,,34.0,24.0,12.9,11.7,6.3,1.22140465,0.07440001,,,,,,False,True,False,True,17694,TEST,9686
426,3403,3877023,Scanning times,high-field horizontal open MR scanner,short-bore MR scanner,continuous,,49.0,,44.0,32.0,22.0,20.0,9.0,0.69457406,0.04572916,,,,,,False,False,False,True,17694,TEST,9686
427,3404,3877023,The mean signal-to-noise (SNR) values,short-bore MR scanner,high-field horizontal open MR scanner,continuous,,44.0,,49.0,17.97,6.58,11.28,4.35,1.20253898,0.05091017,,,,,,False,False,False,True,17694,TEST,9686
428,3261,3475525,Scores on the saturated fat quiz,MTL group,No label group,continuous,,98.0,,99.0,90.7,20.4,33.6,16.3,3.08231109,0.0444184,,,,,,False,True,False,True,9086,TEST,4934
429,3261,3475525,Scores on the saturated fat quiz,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,92.3,15.1,33.6,16.3,3.71430281,0.0577096,,,,,,False,True,False,True,9086,TEST,4934
430,3261,3475525,Scores on the saturated fat quiz,MTL group,choices group,continuous,,98.0,,98.0,90.7,20.4,35.7,15.9,2.99563986,0.04330066,,,,,,False,True,False,True,9086,TEST,4934
431,3261,3475525,Scores on the saturated fat quiz,MTL+caloric intake group,choices group,continuous,,90.0,,98.0,92.3,15.1,35.7,15.9,3.63162908,0.0563916,,,,,,False,True,False,True,9086,TEST,4934
432,3261,3475525,Scores on sugar quiz,MTL group,No label group,continuous,,98.0,,99.0,90.0,20.7,47.2,19.6,2.11539588,0.03166271,,,,,,False,True,False,True,9086,TEST,4934
433,3261,3475525,Scores on sugar quiz,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,92.6,15.5,47.2,19.6,2.54502741,0.03834748,,,,,,False,True,False,True,9086,TEST,4934
434,3261,3475525,Scores on sugar quiz,MTL group,choices group,continuous,,98.0,,98.0,90.0,20.7,41.9,19.4,2.38845924,0.03496107,,,,,,False,True,False,True,9086,TEST,4934
435,3261,3475525,Scores on sugar quiz,MTL+caloric intake group,choices group,continuous,,90.0,,98.0,92.6,15.5,41.9,19.4,2.86225472,0.04310376,,,,,,False,True,False,True,9086,TEST,4934
436,3261,3475525,Scores on sodium quiz,MTL group,No label group,continuous,,98.0,,99.0,93.5,16.4,42.6,20.7,2.71359845,0.03899447,,,,,,False,True,False,True,9086,TEST,4934
437,3261,3475525,Scores on sodium quiz,MTL+caloric intake group,No label group,continuous,,90.0,,99.0,94.1,15.6,42.6,20.7,2.78020714,0.04166067,,,,,,False,True,False,True,9086,TEST,4934
438,3261,3475525,Scores on sodium quiz,MTL group,choices group,continuous,,98.0,,98.0,93.5,16.4,47.1,21.1,2.44594908,0.03567007,,,,,,False,True,False,True,9086,TEST,4934
439,3261,3475525,Scores on sodium quiz,MTL+caloric intake group,choices group,continuous,,90.0,,98.0,94.1,15.6,47.1,21.1,2.50703599,0.03803123,,,,,,False,True,False,True,9086,TEST,4934
440,8803,4467620,decrease in exercise intensity as time elapsed (at time 10),Hot + Cooling conditions,Hot conditions,continuous,,8.0,,8.0,114.6,35.6,123.9,30.2,-0.2663137,0.25221634,,,,,Added the last timepoint to the outcome name. Since there are 10 different time points.,False,True,False,True,7288,TEST,4607
441,8804,4467620,weight reduction,Hot + Cooling conditions,Hot conditions,continuous,,8.0,,8.0,68.6,7.7,68.8,7.5,-0.0248738,0.25001933,,,,,The numerical values are from Exercise state.,False,True,False,True,7288,TEST,4607
442,8805,4467620,accuracy of the cognitive tasks,Exercise - Hot + Cooling conditions,At rest - Hot + Cooling conditions,continuous,,8.0,,8.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,False,False,7288,TEST,4607
443,8801,4467620,accuracy of the cognitive tasks,Exercise - Hot condition,At rest - Hot condition,continuous,,8.0,,8.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,False,False,7288,TEST,4607
444,8802,4467620,differences in the accuracy,Hot + Cooling conditions,Hot conditions,continuous,,8.0,,8.0,,,,,cannot calculate,cannot calculate,,,,,,True,False,False,False,7288,TEST,4607
445,4098,4140238,ocular itching for visit 3B at 7 min,bepotastine besilate ophthalmic solution (BBOS) 1.5%,placebo,continuous,,70.0,,70.0,1.2,,2.1,,cannot calculate,cannot calculate,,,,,"Original outcome name is ""ocular itching"". However, due to many different visits and data from timepoints. We specified this in the outcome. Visit 3B was the first study they conducted and 7 min is the last timepoint. No SD information was given",False,True,False,False,12685,TEST,6812
446,4002,4879328,waist circumference,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104.0,,114.0,-0.89,3.32,0.3,3.54,-0.3450435,0.01866038,,,,,Back calculated SD using CI.,False,True,False,True,12872,TEST,8442
447,4003,4879328,effects for walking,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104.0,,114.0,-0.55,2.29,0.31,3.84,-0.2681458,0.01855223,,,,,Back calculated SD using CI.,False,True,False,True,12872,TEST,8442
448,4003,4879328,effects for vigorous activity,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104.0,,114.0,0.2,1.56,-0.4,2.48,0.28575833,0.0185746,,,,,Back calculated SD using CI.,False,True,False,True,12872,TEST,8442
449,4004,4879328,FFBQ Total Index Score,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104.0,,114.0,0.07,0.26,0.01,0.33,0.20018961,0.01847923,,,,,Back calculated SD using CI.,False,True,False,True,12872,TEST,8442
450,4005,4879328,weekly moderate physical activity sessions,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104.0,,114.0,0.19,1.82,-0.68,2.32,0.41353429,0.01877954,,,,,Back calculated SD using CI.,False,True,False,True,12872,TEST,8442
451,4006,4879328,accelerometer-assessed moderate to vigorous physical activity (MVPA),"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,99.0,,108.0,7.41,66.12,-16.1,66.25,0.35389959,0.01966279,,,,,Values are from Accelerometer PA in Table 2. Back calculated SD using CI.,False,True,False,True,12872,TEST,8442
452,4001,4879328,weight loss,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,continuous,,104.0,,114.0,-0.89,3.33,0.3,3.54,-0.3445812,0.01865965,,,,,Back calculated SD using CI.,False,True,False,True,12872,TEST,8442
453,4432,5726464,Glucose,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,False,True,False,False,6563,TEST,4244
454,4432,5726464,insulin,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,False,True,False,False,6563,TEST,4244
455,4422,4483334,Amount of calcium and phosphate on enamel surface,CPP-ACP plus laser (group D),Distilled and deionized water (group A),continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Original outcome was ""Amount of calcium and phosphate on enamel surface"" but changed to ""Total weight percentage of calcium"" since this seemed more accurate. All numerical values are in a graphical format of table.",False,True,True,False,1396,TEST,1236
456,4423,4483334,Total weight percentage of calcium,CPP-ACP plus laser (group D),Nd:YAG laser (group B),continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Original outcome was ""Amount of calcium and phosphate on enamel surface"" but changed to ""Total weight percentage of calcium"" since this seemed more accurate. All numerical values are in a graphical format of table.",False,True,True,False,1396,TEST,1236
457,4424,4483334,Total weight percentage of calcium,CPP-ACP plus laser (group D),CPP-ACP crème (group C),continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Original outcome was ""Amount of calcium and phosphate on enamel surface"" but changed to ""Total weight percentage of calcium"" since this seemed more accurate. All numerical values are in a graphical format of table.",False,True,True,False,1396,TEST,1236
458,4425,4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),Distilled and deionized water (group A),continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,All numerical values are in a graphical format of table.,False,True,True,False,1396,TEST,1236
459,4425,4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),Nd:YAG laser (group B),continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,All numerical values are in a graphical format of table.,False,True,True,False,1396,TEST,1236
460,4425,4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),CPP-ACP crème (group C),continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,All numerical values are in a graphical format of table.,False,True,True,False,1396,TEST,1236
461,4430,5726464,25(OH)D levels,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,False,True,False,False,6563,TEST,4244
462,4431,5726464,Lipid profile: total cholesterol,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,False,True,False,False,6563,TEST,4244
463,4431,5726464,Lipid profile: HDL-c,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,False,True,False,False,6563,TEST,4244
464,4431,5726464,Lipid profile: LDL-c,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,False,True,False,False,6563,TEST,4244
465,4431,5726464,Lipid profile: Triglycerides,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,False,True,False,False,6563,TEST,4244
466,4433,5726464,Changes in body mass index,Vitamin D plus calcium supplementation,Placebo,continuous,,79.0,,86.0,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,False,True,False,False,6563,TEST,4244
467,4434,5726464,Metabolic syndrome,Vitamin D plus calcium supplementation,Placebo,binary,9.0,66.0,11.0,75.0,,,,,,,-0.0848389,0.23518906,-0.0728373,0.17353535,,False,True,False,True,6563,TEST,4244
468,4802,5515881,memory score,demanding balance training program,relaxation group,continuous,,,,,9.44,5.48,8.0,4.16,cannot calculate,cannot calculate,,,,,Group sizes are in methods section only. Numerical values are from posttest.,True,True,False,False,4475,TEST,3500
469,4799,5515881,dynamic balance performance on the stability platform,demanding balance training program,relaxation group,continuous,,,,,7.54,2.57,6.29,1.84,cannot calculate,cannot calculate,,,,,Group sizes are in methods section only. Numerical values are from posttest.,True,True,False,False,4475,TEST,3500
470,4800,5515881,center of pressure (CoP) sway velocity,demanding balance training program,relaxation group,continuous,,,,,0.63,0.11,0.67,0.18,cannot calculate,cannot calculate,,,,,Group sizes are in methods section only. Numerical values are from posttest.,True,True,False,False,4475,TEST,3500
471,4803,5515881,spatial score,demanding balance training program,relaxation group,continuous,,,,,0.443,0.75,0.04,0.91,cannot calculate,cannot calculate,,,,,Group sizes are in methods section only. Numerical values are from posttest.,True,True,False,False,4475,TEST,3500
472,5710,3343759,improvment in ANELT by day 21,higher level of education (>12 years),<12 years of education,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Median is reported. Group sizes are only available in methods section.,False,True,False,False,3838,TEST,2633
473,5711,3343759,aphasia types,very early speech and language therapy (SLT),control,binary,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Numerical data is in figure and group sizes are not available in abstract or results sections.,True,False,False,False,3838,TEST,2633
474,5522,4144850,Independent household latrines number,Total Sanitation Campaign,Control,binary,673.0,1525.0,366.0,1514.0,,,,,,,0.90730205,0.00626291,0.60187274,0.00290188,Used percent to calculate outcomes for binary variables.,False,True,False,True,24614,TEST,13328
475,5523,4144850,Open defecation - adult men,Total Sanitation Campaign,Control,binary,1138.0,1525.0,1273.0,1514.0,,,,,,,-0.5857317,0.00839764,-0.1193432,0.00034804,Used percent to calculate outcomes for binary variables.,False,True,False,True,24614,TEST,13328
476,5523,4144850,Open defecation - adult women,Total Sanitation Campaign,Control,binary,1116.0,1525.0,1264.0,1514.0,,,,,,,-0.6167847,0.00813218,-0.1317697,0.00037096,Used percent to calculate outcomes for binary variables.,False,True,False,True,24614,TEST,13328
477,5523,4144850,Open defecation - children,Total Sanitation Campaign,Control,binary,1279.0,1525.0,1350.0,1514.0,,,,,,,-0.4594912,0.0116852,-0.0612653,0.00020636,Used percent to calculate outcomes for binary variables.,False,True,False,True,24614,TEST,13328
478,5525,4144850,Helminth infections,Total Sanitation Campaign,Control,binary,34.0,581.0,32.0,569.0,,,,,,,0.04217391,0.06435212,0.0397543,0.05718313,Used percent to calculate outcomes for binary variables.,False,True,False,True,24614,TEST,13328
479,5526,4144850,Anemia,Total Sanitation Campaign,Control,binary,1078.0,1919.0,976.0,1922.0,,,,,,,0.21705107,0.00419838,0.10096226,0.00091084,Used percent to calculate outcomes for binary variables.,False,True,False,True,24614,TEST,13328
480,4801,5515881,VO2peak,demanding balance training program,relaxation group,continuous,,,,,32.07,6.52,31.947,7.89,cannot calculate,cannot calculate,,,,,Group sizes are in methods section only. Numerical values are from posttest.,True,True,False,False,4475,TEST,3500
481,5521,4144850,Sanitation facility improvement,Total Sanitation Campaign,Control,binary,630.0,1522.0,342.0,1512.0,,,,,,,0.88220198,0.00648706,0.6043171,0.00319287,Used percent to calculate outcomes for binary variables.,False,True,False,True,24614,TEST,13328
482,5524,4144850,E. coli contaminated water,Total Sanitation Campaign,Control,binary,310.0,404.0,331.0,403.0,,,,,,,-0.3321747,0.03077414,-0.0680244,0.00129032,Used percent to calculate outcomes for binary variables.,False,True,False,True,24614,TEST,13328
483,5712,3343759,Amsterdam-Nijmegen everyday language test (ANELT),very early speech and language therapy (SLT),control,continuous,,59.0,,55.0,,,,,cannot calculate,cannot calculate,,,,,"Median values are reported. Group size is based on ANELT by day 21, intent-to-treat.",False,True,False,False,3838,TEST,2633
484,5713,3343759,history of myocardial infarction,very early speech and language therapy (SLT),control,binary,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Numerical data are only in methods section.,False,True,False,False,3838,TEST,2633
485,5714,3343759,communication ability,very early speech and language therapy (SLT),control,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Unclear outcome.,False,False,False,False,3838,TEST,2633
486,6382,3786549,Improvement in Vaginal Maturation Index,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44.0,,44.0,35.2,21.7,9.9,14.5,1.35893992,0.05594726,,,,,Numerical values based on intention-to-treat,False,True,False,True,9725,TEST,6231
487,6383,3786549,Baseline characteristics: menopause,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44.0,,44.0,13.11,7.02,13.0,6.94,0.01562115,0.04545593,,,,,,False,True,False,True,9725,TEST,6231
488,6383,3786549,Baseline characteristics: height,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44.0,,44.0,154.86,5.45,153.43,5.88,0.25003828,0.04580977,,,,,,False,True,False,True,9725,TEST,6231
489,6383,3786549,Baseline characteristics: weight,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44.0,,44.0,56.16,8.1,57.82,8.24,-0.201397,0.045685,,,,,,False,True,False,True,9725,TEST,6231
490,6383,3786549,Baseline characteristics: deliveries,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,continuous,,44.0,,44.0,2.14,1.76,2.64,1.79,-0.2792152,0.04589751,,,,,,False,True,False,True,9725,TEST,6231
491,6484,5419060,Sample rejection rate: CHC A,Phlebotomy training programme,Control,binary,79.0,10218.0,60.0,7557.0,,,,,,,-0.0267831,0.02955691,-0.0265733,0.0290947,,False,True,False,True,9292,TEST,5719
492,6484,5419060,Sample rejection rate: CHC B,Phlebotomy training programme,Control,binary,48.0,4114.0,45.0,3973.0,,,,,,,0.0300092,0.04355608,0.02966421,0.04256078,,False,True,False,True,9292,TEST,5719
493,6484,5419060,Sample rejection rate: CDC C,Phlebotomy training programme,Control,binary,37.0,2279.0,38.0,2321.0,,,,,,,-0.0085462,0.05422687,-0.0084069,0.05247318,,False,True,False,True,9292,TEST,5719
494,6484,5419060,Sample rejection rate: CDC D,Phlebotomy training programme,Control,binary,7.0,630.0,8.0,589.0,,,,,,,-0.2033272,0.27118345,-0.200825,0.26457205,,False,True,False,True,9292,TEST,5719
495,6488,5419060,Request-form errors: CHC A,Phlebotomy training programme,Control,binary,8.0,10218.0,11.0,7557.0,,,,,,,-0.6208037,0.21613955,-0.6201303,0.2156789,,False,True,False,True,9292,TEST,5719
496,6488,5419060,Request-form errors: CHC B,Phlebotomy training programme,Control,binary,12.0,4114.0,11.0,3973.0,,,,,,,0.05228567,0.17473861,0.05213706,0.17374765,,False,True,False,True,9292,TEST,5719
497,6488,5419060,Request-form errors: CDC C,Phlebotomy training programme,Control,binary,6.0,2279.0,3.0,2321.0,,,,,,,0.71275138,0.50087135,0.71140856,0.49913036,,False,True,False,True,9292,TEST,5719
498,6488,5419060,Request-form errors: CDC D,Phlebotomy training programme,Control,binary,0.0,630.0,0.0,589.0,,,,,,,-0.0672384,4.0032824,-0.0671833,3.9967203,,False,True,False,True,9292,TEST,5719
499,6489,5419060,Preanalytical errors: CHC A,Phlebotomy training programme,Control,binary,27.0,10218.0,17.0,7557.0,,,,,,,0.16134073,0.09609132,0.16094694,0.09563037,,False,True,False,True,9292,TEST,5719
500,6489,5419060,Preanalytical errors: CHC B,Phlebotomy training programme,Control,binary,12.0,4114.0,10.0,3973.0,,,,,,,0.14784821,0.18382945,0.14744724,0.18283856,,False,True,False,True,9292,TEST,5719
501,6489,5419060,Preanalytical errors: CDC C,Phlebotomy training programme,Control,binary,10.0,2279.0,15.0,2321.0,,,,,,,-0.3892899,0.16754104,-0.3872037,0.16579703,,False,True,False,True,9292,TEST,5719
502,6489,5419060,Preanalytical errors: CDC D,Phlebotomy training programme,Control,binary,2.0,630.0,4.0,589.0,,,,,,,-0.7640755,0.75330176,-0.7604408,0.74671491,,False,True,False,True,9292,TEST,5719
503,6485,5419060,Phlebotomy questionnaire score: CHC A,Phlebotomy training programme,Control,continuous,,23.0,,23.0,96.0,3.89,63.0,12.31,3.55292234,0.22416584,,,,,Back calculated SD using CI,False,False,False,True,9292,TEST,5719
504,6485,5419060,Phlebotomy questionnaire score: CHC B,Phlebotomy training programme,Control,continuous,,23.0,,23.0,93.0,1.37,58.0,7.12,6.70952589,0.57627976,,,,,Back calculated SD using CI,False,False,False,True,9292,TEST,5719
505,6485,5419060,Phlebotomy questionnaire score: CDC C,Phlebotomy training programme,Control,continuous,,23.0,,23.0,97.0,3.85,60.0,5.25,7.89939403,0.76522202,,,,,Back calculated SD using CI,False,False,False,True,9292,TEST,5719
506,6485,5419060,Phlebotomy questionnaire score: CDC D,Phlebotomy training programme,Control,continuous,,23.0,,23.0,97.0,1.21,63.0,4.31,10.5566479,1.29829148,,,,,Back calculated SD using CI,False,False,False,True,9292,TEST,5719
507,6486,5419060,Techinque related rejections: CHC A,Phlebotomy training programme,Control,binary,20.0,10218.0,20.0,7557.0,,,,,,,-0.3023674,0.10023074,-0.3016766,0.09976981,,False,True,False,True,9292,TEST,5719
508,6486,5419060,Techinque related rejections: CHC B,Phlebotomy training programme,Control,binary,15.0,4114.0,8.0,3973.0,,,,,,,0.59537147,0.19216284,0.59373435,0.1911719,,False,True,False,True,9292,TEST,5719
509,6486,5419060,Techinque related rejections: CDC C,Phlebotomy training programme,Control,binary,18.0,2279.0,15.0,2321.0,,,,,,,0.20202879,0.12309816,0.20058293,0.12135258,,False,True,False,True,9292,TEST,5719
510,6486,5419060,Techinque related rejections: CDC D,Phlebotomy training programme,Control,binary,2.0,630.0,4.0,589.0,,,,,,,-0.7640755,0.75330176,-0.7604408,0.74671491,,False,True,False,True,9292,TEST,5719
511,6550,4033571,Overall seizure median percent improvement,Extended-release oxcarbazepine 2400 mg,Control,continuous,,111.0,,117.0,-42.9,,-28.7,,cannot calculate,cannot calculate,,,,,SD was not given,False,False,False,False,8206,TEST,5593
512,6553,4033571,Adverse effects,Extended-release oxcarbazepine 1200 mg,Control,binary,69.0,123.0,67.0,121.0,,,,,,,0.02941389,0.06645516,0.01302008,0.01302358,,False,True,False,True,8206,TEST,5593
513,6549,4033571,Overall seizure median percent reduction,Extended-release oxcarbazepine 1200 mg,Control,continuous,,109.0,,117.0,-38.3,,-28.7,,cannot calculate,cannot calculate,,,,,SD was not given,False,False,False,False,8206,TEST,5593
514,6551,4033571,Seizure median percent improvement in North America,Extended-release oxcarbazepine 1200 mg,Control,continuous,,,,,-34.5,,-13.3,,cannot calculate,cannot calculate,,,,,"Group sizes are only in figure, and SD is not available.",True,False,False,False,8206,TEST,5593
515,6552,4033571,Seizure median percent improvement in North America,Extended-release oxcarbazepine 2400 mg,Control,continuous,,,,,-52.7,,-13.3,,cannot calculate,cannot calculate,,,,,"Group sizes are only in figure, and SD is not available.",True,False,False,False,8206,TEST,5593
516,6554,4033571,Adverse effects,Extended-release oxcarbazepine 2400 mg,Control,binary,85.0,123.0,67.0,121.0,,,,,,,0.58935652,0.07152439,0.22156483,0.01029553,,False,True,False,True,8206,TEST,5593
517,6695,5154016,24 h drainage volume,Stypro hemostatic sponge,Gelatin sponge,continuous,,30.0,,30.0,187.9,82.0,230.8,75.0,-0.538859,0.06908641,,,,,,False,True,False,True,3046,TEST,2156
518,6699,5154016,Second 24 h drainage volume,Stypro hemostatic sponge,Gelatin sponge,continuous,,30.0,,30.0,53.7,3.8,63.5,14.2,-0.9305774,0.07388312,,,,,,False,True,False,True,3046,TEST,2156
519,6700,5154016,Second 24 h drainage volume,Collagen hemostatic sponge,Gelatin sponge,continuous,,30.0,,30.0,63.3,8.9,63.5,14.2,-0.0166581,0.06666898,,,,,,False,True,False,True,3046,TEST,2156
520,6696,5154016,24 h drainage volume,Collagen hemostatic sponge,Gelatin sponge,continuous,,30.0,,30.0,185.2,68.0,230.8,75.0,-0.6287208,0.06996075,,,,,,False,True,False,True,3046,TEST,2156
521,6697,5154016,Total drainage volume,Stypro hemostatic sponge,Gelatin sponge,continuous,,30.0,,30.0,231.5,18.1,318.5,26.7,-3.7647135,0.18477557,,,,,,False,True,False,True,3046,TEST,2156
522,6698,5154016,Total drainage volume,Collagen hemostatic sponge,Gelatin sponge,continuous,,30.0,,30.0,248.5,18.8,318.5,26.7,-2.9921679,0.14127557,,,,,,False,True,False,True,3046,TEST,2156
523,6741,5325897,First test results,Evaluation with feedback,Evaluation without feedback,continuous,,15.0,,15.0,10.24,0.77,9.73,0.77,0.64440958,0.1402544,,,,,,False,False,False,True,4260,TEST,2410
524,6741,5325897,Second test results,Evaluation with feedback,Evaluation without feedback,continuous,,15.0,,15.0,17.73,0.46,12.13,0.47,11.7163546,2.42121609,,,,,,False,False,False,True,4260,TEST,2410
525,6742,5325897,Final test results,Evaluation with feedback,Evaluation without feedback,continuous,,15.0,,15.0,18.53,0.22,18.99,0.22,-2.0343126,0.20230713,,,,,,False,False,False,True,4260,TEST,2410
526,6916,4411165,tympanic temperature from Pre to P20 (-0.28 ±0.11°C),"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10.0,,10.0,-0.28,0.11,-0.14,0.05,-1.5691765,0.26155787,,,,,Values on mean change are based on what is reported in abstract. ,True,False,False,True,3146,TEST,2589
527,6918,4411165,systolic BP,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10.0,,10.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values are only in the figures.,True,False,False,False,3146,TEST,2589
528,6919,4411165,diastolic BP,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10.0,,10.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values are only in the figures.,True,False,False,False,3146,TEST,2589
529,6915,4411165,effects of cryostimulation on the ANS - heart rate,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10.0,,10.0,-7.7,2.3,-5.02,1.07,-1.430817,0.25118093,,,,,"Changed from original outcome but adding ""- heart rate"" to make it more specific. Numbers are mean change.",True,False,False,True,3146,TEST,2589
530,6917,4411165,Tskin of the head,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",continuous,,10.0,,10.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values are only in the figures.,True,False,False,False,3146,TEST,2589
531,7830,4230312,improvement of disorder,quetiapine 600 mg/day,placebo,continuous,,289.0,,204.0,-14.88,10.54,-11.61,10.12,-0.3148988,0.00846274,,,,,Back calculated SD from SE.,True,False,False,True,6201,TEST,5058
532,7829,4230312,improvement of disorder,quetiapine 300 mg/day,placebo,continuous,,283.0,,204.0,-15.58,10.43,-11.61,10.12,-0.3847888,0.00858754,,,,,Back calculated SD from SE.,True,False,False,True,6201,TEST,5058
533,8166,5800236,Months of sick leave,Nacadia® nature-based therapy,Cognitive behavioral therapy,continuous,,37.0,,35.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values were not given for this outcome.,True,False,False,False,4517,TEST,2571
534,7794,3508963,Pain relief,Intravenous lidocaine,Intravenous morphine,continuous,,120.0,,120.0,1.13,1.15,2.23,1.57,-0.7968282,0.01798945,,,,,Values from 30 minutes.,False,True,False,True,3561,TEST,2387
535,7793,3508963,Response to treatment,Intravenous lidocaine,Intravenous morphine,binary,108.0,120.0,84.0,120.0,,,,,,,1.34992672,0.13227513,0.25131443,0.00449735,,False,False,False,True,3561,TEST,2387
536,7795,3508963,Baseline characteristics - age,Intravenous lidocaine,Intravenous morphine,continuous,,120.0,,120.0,35.23,12.37,37.71,11.08,-0.2105282,0.016759,,,,,,False,True,False,True,3561,TEST,2387
537,7795,3508963,Baseline characteristics - hydronephrosis in left kidney,Intravenous lidocaine,Intravenous morphine,binary,52.0,120.0,52.0,120.0,,,,,,,0,0.0678733,0,0.02179487,,False,True,False,True,3561,TEST,2387
538,7795,3508963,Baseline characteristics - hydronephrosis in right kidney,Intravenous lidocaine,Intravenous morphine,binary,57.0,120.0,53.0,120.0,,,,,,,0.13431725,0.06721017,0.07275935,0.01974512,,False,True,False,True,3561,TEST,2387
539,7795,3508963,Baseline characteristics - did not have hydronephrosis,Intravenous lidocaine,Intravenous morphine,binary,11.0,120.0,15.0,120.0,,,,,,,-0.3475425,0.17627388,-0.3101549,0.14090909,,False,True,False,True,3561,TEST,2387
540,7795,3508963,Baseline characteristics - history of reurrent stone,Intravenous lidocaine,Intravenous morphine,binary,49.0,120.0,64.0,120.0,,,,,,,-0.504391,0.06797481,-0.2670628,0.0193665,,False,True,False,True,3561,TEST,2387
541,7795,3508963,Baseline characteristics - history of first stone,Intravenous lidocaine,Intravenous morphine,binary,70.0,120.0,56.0,120.0,,,,,,,0.47000363,0.06776786,0.22314355,0.01547619,,False,True,False,True,3561,TEST,2387
542,7795,3508963,Baseline characteristics - right kidney stone,Intravenous lidocaine,Intravenous morphine,binary,60.0,120.0,57.0,120.0,,,,,,,0.10008346,0.06675021,0.05129329,0.01754386,,False,True,False,True,3561,TEST,2387
543,7795,3508963,Baseline characteristics - left kidney stone,Intravenous lidocaine,Intravenous morphine,binary,60.0,120.0,63.0,120.0,,,,,,,-0.1000835,0.06675021,-0.0487902,0.01587302,,False,True,False,True,3561,TEST,2387
544,7792,3508963,Pain score after 5 minutes,Intravenous lidocaine,Intravenous morphine,continuous,,120.0,,120.0,3.18,2.27,4.45,2.16,-0.5713783,0.01734682,,,,,,False,True,False,True,3561,TEST,2387
545,8460,3263860,HbA1c reduction,Real-Time Continuous Glucose Monitoring,Control,continuous,,69.0,,68.0,-0.1,0.6,-0.1,0.6,0,0.02919864,,,,,Mean change,False,True,True,True,3178,TEST,2587
546,8461,3263860,Severe hypoglycemia,Real-Time Continuous Glucose Monitoring,Control,binary,3.0,73.0,5.0,71.0,,,,,,,-0.5696661,0.56277056,-0.5386052,0.5055502,,False,True,True,True,3178,TEST,2587
547,8463,3263860,Serious skin reactions,Real-Time Continuous Glucose Monitoring,Control,binary,0.0,69.0,0.0,68.0,,,,,,,-0.014493,4.02898703,-0.0143887,3.97122153,Unclear group sizes. Used the group size for 26-week visit.,False,False,True,True,3178,TEST,2587
548,8462,3263860,Diabetic ketoacidosis,Real-Time Continuous Glucose Monitoring,Control,binary,0.0,69.0,0.0,68.0,,,,,,,-0.014493,4.02898703,-0.0143887,3.97122153,Unclear group sizes. Used the group size for 26-week visit.,False,False,True,True,3178,TEST,2587
549,8464,3263860,PAID questionnaire fear of hypoglycemia,Real-Time Continuous Glucose Monitoring,Control,continuous,,69.0,,68.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values in Table which is a graphic,False,True,True,False,3178,TEST,2587
550,9719,3648394,LF:HF component of HRV,10-week yoga program,Control,continuous,,18.0,,19.0,0.35,0.43,0.04,0.38,0.74878609,0.1157639,,,,,Numerical values are from Week 11.,False,True,False,True,9556,TEST,6245
551,9724,3648394,Push-up test,10-week yoga program,Control,continuous,,18.0,,19.0,21.0,11.0,20.0,13.0,0.08105953,0.10827593,,,,,Numerical values are from Week 11.,False,True,False,True,9556,TEST,6245
552,9725,3648394,Quality of life - PCS (SF36),10-week yoga program,Control,continuous,,18.0,,19.0,47.5,2.7,46.9,4.8,0.1496389,0.10848973,,,,,"Original outcome was just ""Quality of Life"". Numerical values are from Week 11.",False,True,False,True,9556,TEST,6245
553,9725,3648394,Quality of life - MCS (SF36),10-week yoga program,Control,continuous,,18.0,,19.0,47.5,10.6,48.5,7.7,-0.1060797,0.1083392,,,,,"Original outcome was just ""Quality of Life"". Numerical values are from Week 11.",False,True,False,True,9556,TEST,6245
554,9720,3648394,pNN50,10-week yoga program,Control,continuous,,18.0,,19.0,20.7,25.3,19.4,18.4,0.05775336,0.10823221,,,,,Numerical values are from Week 11.,False,True,False,True,9556,TEST,6245
555,9721,3648394,Flexibility,10-week yoga program,Control,continuous,,18.0,,19.0,31.0,8.7,26.4,10.4,0.46823146,0.11114985,,,,,Numerical values are from Week 11 data for sit and reach test.,False,True,False,True,9556,TEST,6245
556,9828,3136370,Fibromyalgia Impact Questionnaire scores,Soy shake,Control,continuous,,12.0,,16.0,-17.1,68.08,-19.57,93.53,0.02864501,0.14584799,,,,,From per protocol,False,True,False,True,6022,TEST,3786
557,9830,3136370,Fibromyalgia Impact Questionnaire scores,Soy shake,Casein shake (Placebo),continuous,,12.0,,16.0,-17.1,68.08,-19.57,93.53,0.02864501,0.14584799,,,,,From per protocol,False,True,False,True,6022,TEST,3786
558,9831,3136370,Center for Epidemiologic Studies Depression Scale score,Soy shake,Control,continuous,,12.0,,16.0,-4.0,12.35,-8.0,65.41,0.07716042,0.14593965,,,,,From per protocol,False,True,False,True,6022,TEST,3786
559,9833,3136370,Center for Epidemiologic Studies Depression Scale score,Soy shake,Casein shake (Placebo),continuous,,12.0,,16.0,-4.0,12.35,-8.0,65.41,0.07716042,0.14593965,,,,,From per protocol,False,True,False,True,6022,TEST,3786
560,9834,3496170,Learned irrelevance index,Biperiden,Placebo,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Group sizes are not available and numerical data in figure.,True,False,True,False,2318,TEST,1990
561,9835,3496170,P3a amplitude,Biperiden,Placebo,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Group sizes are not available and numerical data in figure.,True,False,True,False,2318,TEST,1990
562,9836,3496170,P3a latency,Biperiden,Placebo,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Group sizes are not available and numerical data in figure.,True,False,True,False,2318,TEST,1990
563,9837,3496170,Self-report questionnaire,Biperiden,Placebo,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,No numerical values are given.,False,False,True,False,2318,TEST,1990
564,9838,3496170,N1 latency,Biperiden,Placebo,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Group sizes are not available and numerical data in figure.,True,False,True,False,2318,TEST,1990
565,9839,3496170,N1 amplitude,Biperiden,Placebo,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Group sizes are not available and numerical data is not given.,False,False,True,False,2318,TEST,1990
566,8556,5541727,Knee Injury and Osteoarthritis Outcome Score improvement,Allogeneic mesenchymal precursor cells,Control,continuous,,11.0,,6.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,True,False,False,False,6118,TEST,5345
567,8560,5541727,Tibial bone expansion,Allogeneic mesenchymal precursor cells,Control,continuous,,11.0,,6.0,-0.7,1.5,1.0,1.1,-1.1693949,0.29779588,,,,,"Values are from ""total tibial plateau"" for 24 months",False,True,False,True,6118,TEST,5345
568,8555,5541727,Treatment-related serious adverse events,Allogeneic mesenchymal precursor cells,Control,binary,0.0,11.0,0.0,6.0,,,,,,,-0.5705449,4.24080268,-0.5389965,3.77380952,,False,False,False,True,6118,TEST,5345
569,8557,5541727,Activities of daily living,Allogeneic mesenchymal precursor cells,Control,continuous,,11.0,,6.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,True,False,False,False,6118,TEST,5345
570,8558,5541727,Symptom improvement,Allogeneic mesenchymal precursor cells,Control,continuous,,11.0,,6.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,True,False,False,False,6118,TEST,5345
571,8559,5541727,SF-36 bodily pain score improvement,Allogeneic mesenchymal precursor cells,Control,continuous,,11.0,,6.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,True,False,False,False,6118,TEST,5345
572,8561,5541727,medial tibial cartilage volume loss,Allogeneic mesenchymal precursor cells,Control,continuous,,11.0,,6.0,-1.4,4.2,-3.3,5.3,0.39232146,0.2621027,,,,,Values are from 24 months,False,True,False,True,6118,TEST,5345
573,8561,5541727,lateral tibial cartilage volume loss,Allogeneic mesenchymal precursor cells,Control,continuous,,11.0,,6.0,-3.7,3.4,-0.8,3.5,-0.8015134,0.27647057,,,,,Values are from 24 months,False,True,False,True,6118,TEST,5345
574,8565,2952311,Verbal rating scale pain intensity,Acupressure at distal points,Control,continuous,,11.0,,11.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,True,False,False,False,3603,TEST,2475
575,8562,2952311,Verbal rating scale pain intensity,Acupressure at local points,Control,continuous,,11.0,,11.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,True,False,False,False,3603,TEST,2475
576,8563,2952311,State-Trait Anxiety Inventory-I,Acupressure at local points,Control,continuous,,11.0,,11.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,True,False,False,False,3603,TEST,2475
577,8567,2952311,Salivary alpha-amylase,Acupressure at distal points,Acupressure at local points,continuous,,11.0,,11.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,True,False,False,False,3603,TEST,2475
578,8564,2952311,Muscle hardness,Acupressure at local points,Control,continuous,,11.0,,11.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,True,False,False,False,3603,TEST,2475
579,8566,2952311,State-Trait Anxiety Inventory-I,Acupressure at distal points,Control,continuous,,11.0,,11.0,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,True,False,False,False,3603,TEST,2475
580,10217,3504298,Anxious symptoms,Face-based attentional bias modification,Placebo,continuous,,16.0,,14.0,,,,,cannot calculate,cannot calculate,,,,,"F-values given, cant use for point estimates, and values in figure",True,False,False,False,4963,TEST,4205
581,11584,115849,Discontinuation due to lack of efficacy,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
582,10219,3504298,Attentional Function,Word-based attentional bias modification,Face-based attentional bias modification,continuous,,16.0,,16.0,,,,,cannot calculate,cannot calculate,,,,,"F-values given, cant use for point estimates, and values in figure",True,False,False,False,4963,TEST,4205
583,10218,3504298,Difference of cortisol on waking and the highest level of following samples,Word-based attentional bias modification,Placebo,continuous,,16.0,,15.0,,,,,cannot calculate,cannot calculate,,,,,"F-values given, cant use for point estimates, and values in figure",True,False,False,False,4963,TEST,4205
584,10215,3504298,Depressive symptoms,Face-based attentional bias modification,Placebo,continuous,,16.0,,14.0,,,,,cannot calculate,cannot calculate,,,,,"F-values given, cant use for point estimates",False,False,False,False,4963,TEST,4205
585,10216,3504298,Depressive symptoms,Word-based attentional bias modification,Placebo,continuous,,16.0,,15.0,,,,,cannot calculate,cannot calculate,,,,,"F-values given, cant use for point estimates",False,False,False,False,4963,TEST,4205
586,11522,547916,matrix metalloproteinase-9 (MMP-9),doxycycline (100 mg),placebo,continuous,,10.0,,4.0,2.18,1.94,3.26,3.58,-0.4117458,0.35605481,,,,,found in abstract,False,False,False,True,4542,TEST,3636
587,11581,115849,patients discontinued due to lack of efficacy,etoricoxib 90 mg once daily,placebo,binary,44.0,353.0,90.0,357.0,,,,,,,-0.8617127,0.04081995,-0.7043523,0.0282044,found in fig 1,True,False,False,True,6464,TEST,5362
588,11581,115849,patients discontinued due to lack of efficacy,naproxen 500 mg twice daily,placebo,binary,19.0,181.0,90.0,357.0,,,,,,,-1.0557184,0.07366085,-0.8761319,0.05541671,found in fig 1,True,False,False,True,6464,TEST,5362
589,11583,115849,Patient global assessment of disease activity,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
590,11583,115849,investigator global assessment of disease activity,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
591,11583,115849,Tender joint count,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
592,11583,115849,Swollen joint count,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
593,11583,115849,Patient global assessment of pain,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
594,11583,115849,Health Assessment Questionnaire disability,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
595,11583,115849,Serum C-reactive protein,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
596,11583,115849,ACR20 responder criteria,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
597,11583,115849,Discontinuation due to lack of efficacy,etoricoxib 90 mg once daily,placebo,continuous,,353.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
598,11583,115849,Patient global assessment of disease activity,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
599,11583,115849,investigator global assessment of disease activity,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
600,11583,115849,Tender joint count,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
601,11583,115849,Swollen joint count,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
602,11583,115849,Patient global assessment of pain,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
603,11583,115849,Health Assessment Questionnaire disability,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
604,11583,115849,Serum C-reactive protein,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
605,11583,115849,ACR20 responder criteria,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
606,11583,115849,Discontinuation due to lack of efficacy,naproxen 500 mg twice daily,placebo,continuous,,181.0,,357.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
607,11584,115849,Patient global assessment of disease activity,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
608,11584,115849,investigator global assessment of disease activity,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
609,11584,115849,Tender joint count,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
610,11584,115849,Swollen joint count,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
611,11584,115849,Patient global assessment of pain,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
612,11584,115849,Health Assessment Questionnaire disability,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
613,11584,115849,Serum C-reactive protein,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
614,11584,115849,ACR20 responder criteria,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,continuous,,353.0,,181.0,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",False,True,False,False,6464,TEST,5362
615,11602,1863515,haemoglobin level between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,continuous,,754.0,,656.0,-0.4,,0.0,,cannot calculate,cannot calculate,,,,,"given as estimated change and no std given, also in figure and graphic format",True,True,True,False,3963,TEST,3457
616,11602,1863515,leucocyte count between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,continuous,,754.0,,656.0,-423.0,,0.0,,cannot calculate,cannot calculate,,,,,"given as estimated change and no std given, also in figure and graphic format",True,True,True,False,3963,TEST,3457
617,11602,1863515,absolute neutrophil count between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,continuous,,754.0,,656.0,-485.0,,0.0,,cannot calculate,cannot calculate,,,,,"given as estimated change and no std given, also in figure and graphic format",True,True,True,False,3963,TEST,3457
618,11603,1863515,haemoglobin level at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,continuous,,754.0,,656.0,10.7,,11.2,,cannot calculate,cannot calculate,,,,,"means given but no std given, tables and figures in graphic format",True,True,True,False,3963,TEST,3457
619,11603,1863515,leucocyte count at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,continuous,,754.0,,656.0,8818.0,,8362.0,,cannot calculate,cannot calculate,,,,,"means given but no std given, tables and figures in graphic format",True,True,True,False,3963,TEST,3457
620,11603,1863515,absolute neutrophil count at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,continuous,,754.0,,656.0,5639.0,,6150.0,,cannot calculate,cannot calculate,,,,,"means given but no std given, tables and figures in graphic format",True,True,True,False,3963,TEST,3457
621,11904,3493722,eradication rate of H. pylori in ITT,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,71.0,85.0,72.0,84.0,,,,,,,-0.1681369,0.1827353,-0.0258207,0.00430393,"found in abstract and table, assumed binary because given as percentage of population",False,False,False,True,1684,TEST,1549
622,11904,3493722,eradication rate of H. pylori in PP,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,71.0,81.0,72.0,81.0,,,,,,,-0.1193468,0.23908451,-0.0139862,0.00328204,"found in abstract and table, assumed binary because given as percentage of population",False,False,False,True,1684,TEST,1549
623,11905,3493722,side effects,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,19.0,85.0,32.0,84.0,,,,,,,-0.7597079,0.11826386,-0.5331314,0.06021211,found in results section,False,False,False,True,1684,TEST,1549
624,11906,3493722,good compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,74.0,81.0,74.0,81.0,,,,,,,0,0.31274131,0,0.00233567,"found in table 2, assumed binary because proportion of whole given",False,True,True,True,1684,TEST,1549
625,11906,3493722,well compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,8.0,81.0,4.0,81.0,,,,,,,0.74649316,0.40168564,0.69314718,0.35030864,"found in table 2, assumed binary because proportion of whole given",False,True,True,True,1684,TEST,1549
626,11906,3493722,poor compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,binary,2.0,81.0,3.0,81.0,,,,,,,-0.4182041,0.85881207,-0.4054651,0.80864198,"found in table 2, assumed binary because proportion of whole given",False,True,True,True,1684,TEST,1549
627,12232,3510731,Clicked on Results link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,binary,247.0,6051.0,515.0,5892.0,,,,,,,-0.8111953,0.0063486,-0.7614066,0.00565535,found in table 1,False,True,False,True,1665,TEST,1296
628,12233,3510731,Clicked on Protocol link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,binary,202.0,6051.0,362.0,5892.0,,,,,,,-0.6394594,0.00806473,-0.6100046,0.00737794,found in table 1,False,True,False,True,1665,TEST,1296
629,12234,3510731,Median time in seconds (interquartile range) - Results link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,continuous,,6051.0,,5892.0,25.0,,25.3,,cannot calculate,cannot calculate,,,,,"found in table 1, IQ range given rather and std",False,True,False,False,1665,TEST,1296
630,12235,3510731,Median time in seconds (interquartile range) - Protocol link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,continuous,,6051.0,,5892.0,3.5,,3.6,,cannot calculate,cannot calculate,,,,,"found in table 1, IQ range given rather and std",False,True,False,False,1665,TEST,1296
631,12275,3936115,The number of diverticulitis clinical symptom occurrences during 12months,Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,binary,2.0,30.0,7.0,22.0,,,,,,,-1.8769173,0.7452381,-1.5629179,0.56406926,found in table 1,False,True,False,True,2217,TEST,2016
632,12276,3936115,the number of abdominal ultrasound examinations performed for suspected diverticulitis and subsequent number of diverticulitis diagnosed based on abdominal US,Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,binary,1.0,30.0,5.0,22.0,,,,,,,-2.1435204,1.29330629,-1.9195928,1.12121212,found in table 2,False,True,False,True,2217,TEST,2016
633,12277,3936115,"Subjective improvement in observed symptoms based on a single closed-end question (yes or no answer): ""Did you observe adequate relief of diverticulosis related to abdominal pain or discomfort within the past 12 months?""",Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,binary,17.0,30.0,5.0,22.0,,,,,,,1.49203942,0.39457014,0.9136205,0.18003565,found in table 3,False,True,False,True,2217,TEST,2016
634,12289,5777645,HbA1c levels,to peer-led structured patient education,conventional care alone,continuous,,70.0,,70.0,1.05,2.0,0.15,1.7,0.48225433,0.02940203,,,,,SDs found in abstract while group sizes and means found in table 2,False,True,False,True,8661,TEST,5060
635,12290,5777645,Mean BMI change,to peer-led structured patient education,conventional care alone,continuous,,,,,-1.65,2.5,0.05,3.2,,,,,,,SDs found in abstract while group sizes and means found in table 2,False,True,False,True,8661,TEST,5060
636,12291,5777645,Mean waist circumference,to peer-led structured patient education,conventional care alone,continuous,,,,,-3.34,9.3,2.65,10.3,,,,,,,SDs found in abstract while group sizes and means found in table 2,False,True,False,True,8661,TEST,5060
637,12720,4132222,decrease in average lesion,application of a canola phenolic acid-based cream (CPA),placebo,continuous,,30.0,,15.0,,,,,cannot calculate,cannot calculate,,,,,no raw values given and can only be estimated from figure,False,False,False,False,2177,TEST,1885
638,12721,4132222,"higher prevalence of lesion scabbing, a sign of healing",application of a canola phenolic acid-based cream (CPA),placebo,continuous,,30.0,,15.0,,,,,cannot calculate,cannot calculate,,,,,no raw values given and can only be estimated from figure,False,False,False,False,2177,TEST,1885
639,12772,4511433,LDL cholesterol,5 mg elobixibat,placebo,continuous,,12.0,,12.0,,,,,cannot calculate,cannot calculate,,,,,no raw values given and can only be estimated from figure,False,False,False,False,4648,TEST,3874
640,12772,4511433,LDL cholesterol,2.5 mg,placebo,continuous,,12.0,,12.0,,,,,cannot calculate,cannot calculate,,,,,no raw values given and can only be estimated from figure,False,False,False,False,4648,TEST,3874
641,12879,5830087,objective response rate (ORR),"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),binary,29.0,48.0,19.0,23.0,,,,,,,-1.1352878,0.38974592,-0.3128499,0.02280274,found in table 2,False,True,False,True,11942,TEST,10628
642,12880,5830087,disease control rate,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),binary,45.0,48.0,21.0,23.0,,,,,,,0.35667494,0.9031746,0.02643326,0.00552968,found in table 2,False,True,False,True,11942,TEST,10628
643,12880,5830087,duration of objective response,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),continuous,,48.0,,23.0,,,,,cannot calculate,cannot calculate,,,,,"given as median with confidence interval, cannot calculate",False,True,False,False,11942,TEST,10628
644,12880,5830087,progression-free survival,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),continuous,,48.0,,23.0,,,,,cannot calculate,cannot calculate,,,,,"given as median with confidence interval, cannot calculate",False,True,False,False,11942,TEST,10628
645,13025,4675066,The mean cognitive score on the Bayley-III,iodine (150 μg/d),placebo,continuous,,27.0,,26.0,99.4,12.2,101.7,8.2,-0.2172012,0.07594364,,,,,found in table 2,False,True,False,True,6682,TEST,5735
646,13025,4675066,The mean language score on the Bayley-III,iodine (150 μg/d),placebo,continuous,,27.0,,26.0,97.2,12.2,97.9,11.5,-0.058139,0.07553046,,,,,found in table 2,False,True,False,True,6682,TEST,5735
647,13025,4675066,The mean motor score on the Bayley-III,iodine (150 μg/d),placebo,continuous,,27.0,,26.0,93.9,10.8,92.4,9.7,0.14381908,0.07569371,,,,,found in table 2,False,True,False,True,6682,TEST,5735
648,13097,5976307,induction time,etomidate,propofol based on midazolam,continuous,,62.0,,62.0,2.46,0.993,2.21,1.0,0.24933056,0.03250873,,,,,found in table 2,False,True,True,True,2560,TEST,2044
649,13097,5976307,total procedure time,etomidate,propofol based on midazolam,continuous,,62.0,,62.0,29.73,12.23,29.46,16.04,0.01881372,0.03225949,,,,,found in table 2,False,True,True,True,2560,TEST,2044
650,13097,5976307,awake time,etomidate,propofol based on midazolam,continuous,,62.0,,62.0,15.08,10.06,17.07,11.83,-0.1801099,0.03238887,,,,,found in table 2,False,True,True,True,2560,TEST,2044
651,13098,5976307,The incidence rate of all cardiopulmonary adverse events,etomidate,propofol based on midazolam,binary,34.0,62.0,45.0,62.0,,,,,,,-0.7792931,0.1461718,-0.280302,0.01937592,found in table 3,False,True,True,True,2560,TEST,2044
652,13099,5976307,The incidence rate of vital sign fluctuation (VSF),etomidate,propofol based on midazolam,binary,17.0,62.0,31.0,62.0,,,,,,,-0.9734491,0.14556188,-0.6007739,0.05882353,found in table 3,False,True,True,True,2560,TEST,2044
653,13100,5976307,the incidence rate of adverse events disturbing the procedure,etomidate,propofol based on midazolam,binary,16.0,62.0,5.0,62.0,,,,,,,1.37756068,0.30178299,1.16315081,0.23024194,found in table 3,False,True,True,True,2560,TEST,2044
654,13101,5976307,The incidence rate of myoclonus,etomidate,propofol based on midazolam,binary,10.0,62.0,1.0,62.0,,,,,,,2.46221524,1.13562421,2.30258509,1.06774194,found in table 3,False,True,True,True,2560,TEST,2044
655,13175,5773985,mean volume of both the solutions used,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,4.15,0.52,4.12,0.6,0.05259525,0.08002766,,,,,Found in abstract and results,False,False,False,True,2609,TEST,2261
656,13176,5773985,subjective onset of action,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,3.0,1.08,2.92,1.03,0.07461636,0.08005568,,,,,Found in abstract and results,False,False,False,True,2609,TEST,2261
657,13176,5773985,objective onset of action,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,7.4,1.93,7.28,1.59,0.06679907,0.08004462,,,,,Found in abstract and results,False,False,False,True,2609,TEST,2261
658,13177,5773985,duration of surgical procedure,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,32.2,15.5,33.68,18.91,-0.0842565,0.08007099,,,,,Graphic format table,False,True,True,True,2609,TEST,2261
659,13178,5773985,the mean duration of postoperative analgesia,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,508.92,63.3,1840.84,819.51,-2.2556182,0.13087813,,,,,Found in abstract and results,False,False,False,True,2609,TEST,2261
660,13179,5773985,number of analgesic tablets,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,continuous,,25.0,,25.0,1.64,0.99,0.8,1.08,0.7980815,0.08636934,,,,,Graphic format table,False,True,True,True,2609,TEST,2261
661,13216,4458006,amplitude of whisking,facial nerve transection and subsequent repair either at the main trunk of the nerve (group 1),"2 cm distally, at the main bifurcation (group 2)",continuous,,12.0,,12.0,17.2,,6.9,,cannot calculate,cannot calculate,,,,,No std given,False,False,False,False,1302,TEST,1180
662,13294,4987981,"Psoriasis Area and Severity Index (PASI), Erythema, Scaling and Induration (ESI) and Physician global assessment (PGA) scores",metformin or pioglitazone,placebo,continuous,,37.0,,23.0,,,,,cannot calculate,cannot calculate,,,,,Values combined and given in figure,True,False,False,False,9637,TEST,7894
663,13295,4987981,percentage of patients achieving 75 % reduction in PASI and ESI scores,metformin or pioglitazone,placebo,continuous,,37.0,,23.0,,,,,cannot calculate,cannot calculate,,,,,Values combined and given in figure,True,False,False,False,9637,TEST,7894
664,13296,4987981,FPG,metformin,placebo,continuous,,21.0,,23.0,101.9,35.1,97.6,20.8,0.14806913,0.09134645,,,,,Values seperated and found in table,False,True,False,True,9637,TEST,7894
665,13296,4987981,FPG,pioglitazone,placebo,continuous,,16.0,,23.0,103.4,28.9,97.6,20.8,0.23275367,0.1066728,,,,,Values seperated and found in table,False,True,False,True,9637,TEST,7894
666,13296,4987981,total cholesterol,metformin,placebo,continuous,,21.0,,23.0,206.9,36.2,184.4,37.5,0.59900785,0.0951747,,,,,Values seperated and found in table,False,True,False,True,9637,TEST,7894
667,13296,4987981,total cholesterol,pioglitazone,placebo,continuous,,16.0,,23.0,207.2,42.3,184.4,37.5,0.5651889,0.11007363,,,,,Values seperated and found in table,False,True,False,True,9637,TEST,7894
668,13296,4987981,triglycerides levels,metformin,placebo,continuous,,21.0,,23.0,194.3,63.1,181.8,61.3,0.19746629,0.09154041,,,,,Values seperated and found in table,False,True,False,True,9637,TEST,7894
669,13296,4987981,triglycerides levels,pioglitazone,placebo,continuous,,16.0,,23.0,200.1,55.9,181.8,61.3,0.30295813,0.10715497,,,,,Values seperated and found in table,False,True,False,True,9637,TEST,7894
670,13297,4987981,IL-6 and TNF-α levels,metformin or pioglitazone,placebo,continuous,,37.0,,23.0,,,,,cannot calculate,cannot calculate,,,,,Values combined and given in figure,True,False,False,False,9637,TEST,7894
671,13313,4550271,Community knowledge,provider,control,continuous,,14.0,,12.0,,,,,cannot calculate,cannot calculate,,,,,outcome too broad,False,True,False,False,24886,TEST,12978
672,13313,4550271,Community knowledge,provider-school intervention,control,continuous,,14.0,,12.0,,,,,cannot calculate,cannot calculate,,,,,outcome too broad,False,True,False,False,24886,TEST,12978
673,13314,4550271,treatment according to guidelines,provider,control,continuous,,14.0,,12.0,36.4,32.0,22.6,23.0,0.47332022,0.15907021,,,,,mean given as percent and std has no unit,False,True,False,True,24886,TEST,12978
674,13314,4550271,treatment according to guidelines,provider-school intervention,control,continuous,,14.0,,12.0,23.5,26.0,22.6,23.0,0.035327,0.1547859,,,,,mean given as percent and std has no unit,False,True,False,True,24886,TEST,12978
675,13315,4550271,the proportion of patients who tested positive and received (or were prescribed) an ACT,provider,control,continuous,,14.0,,12.0,56.1,31.0,64.2,28.0,-0.2644318,0.1561066,,,,,mean given as percent and std has no unit,False,True,False,True,24886,TEST,12978
676,13315,4550271,the proportion of patients who tested positive and received (or were prescribed) an ACT,provider-school intervention,control,continuous,,14.0,,12.0,56.4,33.0,64.2,28.0,-0.2451619,0.15591776,,,,,mean given as percent and std has no unit,False,True,False,True,24886,TEST,12978
677,13505,5777419,the total cultivable microbiota,probiotic,placebo,continuous,,16.0,,15.0,,,,,cannot calculate,cannot calculate,,,,,median and IQ scores given,False,True,False,False,9410,TEST,4699
678,13505,5777419,the total cultivable microbiota,antibiotic,placebo,continuous,,16.0,,15.0,,,,,cannot calculate,cannot calculate,,,,,median and IQ scores given,False,True,False,False,9410,TEST,4699
679,13506,5777419,attachment gain,probiotic,placebo,continuous,,16.0,,15.0,3.4,0.6,4.3,1.4,-0.8236508,0.14010861,,,,,found in table 2,False,True,False,True,9410,TEST,4699
680,13506,5777419,reduction of PPD,probiotic,placebo,continuous,,16.0,,15.0,2.2,0.3,2.5,0.6,-0.6224049,0.13541486,,,,,found in table 2,False,True,False,True,9410,TEST,4699
681,13506,5777419,reduction of plaque,probiotic,placebo,continuous,,16.0,,15.0,28.1,14.6,27.4,13.0,0.0492187,0.12920574,,,,,found in table 2,False,True,False,True,9410,TEST,4699
682,13506,5777419,attachment gain,antibiotic,placebo,continuous,,16.0,,15.0,4.1,1.0,4.3,1.4,-0.1610069,0.12958478,,,,,found in table 2,False,True,False,True,9410,TEST,4699
683,13506,5777419,reduction of PPD,antibiotic,placebo,continuous,,16.0,,15.0,2.3,0.3,2.5,0.6,-0.4149366,0.13194364,,,,,found in table 2,False,True,False,True,9410,TEST,4699
684,13506,5777419,reduction of plaque,antibiotic,placebo,continuous,,16.0,,15.0,31.8,14.8,27.4,13.0,0.30695109,0.13068633,,,,,found in table 2,False,True,False,True,9410,TEST,4699
685,13760,2836833,Fecal fat loss,1500 mg calcium,500 mg calcium,continuous,,17.0,,17.0,,,,,cannot calculate,cannot calculate,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",False,True,False,False,12992,TEST,7163
686,13761,2836833,Urinary calcium excretion,1500 mg calcium,500 mg calcium,continuous,,17.0,,17.0,,,,,cannot calculate,cannot calculate,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",False,True,False,False,12992,TEST,7163
687,13762,2836833,weight loss,1500 mg calcium,500 mg calcium,continuous,,17.0,,17.0,,,,,cannot calculate,cannot calculate,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",False,True,False,False,12992,TEST,7163
688,13763,2836833,systolic or diastolic blood pressure,1500 mg calcium,500 mg calcium,continuous,,17.0,,17.0,,,,,cannot calculate,cannot calculate,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",False,True,False,False,12992,TEST,7163
689,13830,4210722,vaccination certificates were submitted,a separate reminder card 4 days before the appointment (IG3),no further reminder (IG1),binary,94.0,102.0,84.0,104.0,,,,,,,1.02876872,0.19754306,0.13189607,0.00312375,found in text as fractions of group sizes,False,False,False,True,10493,TEST,8112
690,13830,4210722,vaccination certificates were submitted,a separate reminder card 4 days before the appointment (IG3),reminder card together with the appointment letter (IG2),binary,94.0,102.0,91.0,107.0,,,,,,,0.72558246,0.20912731,0.0802913,0.00247759,found in text as fractions of group sizes,False,False,False,True,10493,TEST,8112
691,13831,4210722,use of a reminder card,a separate reminder card 4 days before the appointment (IG3); reminder card together with the appointment letter (IG2);,no further reminder (IG1),binary,185.0,209.0,84.0,104.0,,,,,,,0.60721747,0.10897683,0.09159567,0.00291009,found in text as fractions of group sizes,False,False,False,True,10493,TEST,8112
692,5635,5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),Duloxetine (D),continuous,,30.0,,30.0,137.0,61.3,91.7,35.5,0.89262531,0.0733065,,,,,found in fig2,True,False,False,True,6401,TEST,5424
693,5636,5712123,postoperative pain at rest,duloxetine 60 and etoricoxib 120mg (group D/E),placebo,continuous,,30.0,,30.0,2.0,,3.0,,cannot calculate,cannot calculate,,,,,values given as score (range),False,True,False,False,6401,TEST,5424
694,5636,5712123,postoperative pain on movement,duloxetine 60 and etoricoxib 120mg (group D/E),placebo,continuous,,30.0,,30.0,3.5,,3.0,,cannot calculate,cannot calculate,,,,,values given as score (range),False,True,False,False,6401,TEST,5424
695,5639,5712123,morphine requirements,E group,P group,continuous,,30.0,,30.0,24.6,4.5,31.9,6.7,-1.2625038,0.0799493,,,,,found in fig3,True,False,False,True,6401,TEST,5424
696,5639,5712123,morphine requirements,D group,P group,continuous,,30.0,,30.0,22.6,4.1,31.9,6.7,-1.6526241,0.08942639,,,,,found in fig3,True,False,False,True,6401,TEST,5424
697,5639,5712123,morphine requirements,D/E group,P group,continuous,,30.0,,30.0,17.9,3.2,31.9,6.7,-2.6318902,0.12439038,,,,,found in fig3,True,False,False,True,6401,TEST,5424
698,5637,5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),Placebo group (P),continuous,,30.0,,30.0,137.0,61.3,62.0,37.2,1.45998637,0.08442967,,,,,found in fig2,True,False,False,True,6401,TEST,5424
699,5638,5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),etoricoxib (E),continuous,,30.0,,30.0,137.0,61.3,105.3,28.4,0.6549502,0.07024133,,,,,found in fig2,True,False,False,True,6401,TEST,5424
